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ABSTRACT
New methods to quantify rare biomarkers from patient samples are critical for developing point-
of-care diagnostic platforms. To be compatible with resource limited settings, these assays have to
provide fast and accurate results without sacrificing ease of use. Biosensing in homogeneous fashion is
the preferred format which satisfies these criteria, but the lack of amplification method is a bottleneck that
limits their use for sensitive applications. To address this issue, this thesis explores physical signal
amplification means to increase the sensitivities of homogeneous assays. We identified several key
applications where the use of these technologies could make a positive impact in improving medical
diagnostics systems and advancing biological research.
We first outline the use of electrokinetic concentration to realize a continuous signal
amplification scheme that increases the sensitivity of homogeneous mobility shift assays. By
simultaneously concentrating and separating reacted and unreacted species (with different mobilities) in
this device, we can perform sensitive, quantitative and ratiometric measurement of target biomarkers.
Using this platform, we improved the sensitivity of aptamer affinity probe capillary electrophoresis to
achieve pM detection limit of IgE and HIV-RT in simple buffer and serum sample. This work is timely
and impactful as it directly addresses the sensitivity shortcomings of using aptamers as low cost and
robust substitutes for antibodies in point-of-care applications.
Next, we presented a herringbone nanofilter array device which can perform continuous size-
selective concentration of biomolecules based on their direct interaction with nanostructures with
comparable critical dimensions. We demonstrated the use of this platform to perform a novel
homogeneous immunoassay for detecting a cardiac biomarker, C-reactive protein, at clinically relevant
concentrations.
Finally, we demonstrated that the concentration-enhanced mobility shift assay platform is a
powerful tool for probing biological activities such as cellular kinase activities. We have developed
technology to isolate, grow and lyse single cells, and used our platform to measure kinase activities from
single cells. Through rational design of peptide substrates and spacers, this platform has the ability to
simultaneously concentrate and separate multiple analytes. This enables users to obtain simultaneous
measurements of multiple cellular kinase activities that could reveal important information about their
functional relationships.
Thesis Supervisor: Jongyoon Han
Title: Associate Professor of Electrical Engineering and Computer Science and Associate Professor of
Biological Engineering
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Chapter 1
Introduction
1.1 Opportunities in micro/nano-fluidics for biomolecule analysis
One of the most pressing issues in analytical chemistry is detecting low abundance analytes from complex
samples such as blood, saliva and urine. Tests for low abundance biomarkers are routinely used for
disease diagnostics, to monitor patient response during therapy, and to help detect recurrence following
treatment. Therefore, there is significant clinical relevance to increase the sensitivity of these tests to
facilitate early detection of the onset of diseases, since these biomarkers get diluted significantly in
biofluids, especially in the early stages of disease progression.
The traditional workflow of biomarker analysis involves taking a sample from a patient, sending
the sample to a laboratory where the analysis is performed with sophisticated equipments, and getting the
results several days later. Several problems associated with this model are the need of good infrastructure
for sample transport, possibility of sample deterioration during storage, and long turnaround time leading
to patient anxiety. In order to address these problems, there has been tremendous interest in developing
point-of-care diagnostic systems, which aims to bring medical testing to near patient care in the form of
portable test kits. Commercial examples of point-of-care diagnostic systems include the over-the-counter
pregnancy test strip, which uses lateral-flow-immunoassays to provide test results in minutes. However,
these tests are usually qualitative and have limited sensitivities. At the same time, certain clinical
applications, such as cancer diagnostics, requires assay sensitivities that are beyond the capabilities
of existing point-of-care diagnostic devices. This calls for a new breed of technology that could perform
more sophisticated operations to achieve better assay sensitivity and specificity.
An answer to this challenge is micro total analysis systems (pTAS), which aims at integrating
multiple biological and chemical analyses in a single chip. Leveraging on the microfabrication techniques
developed for semiconductor manufacturing, microfluidics technology have matured considerably in the
last few decades to deliver performances that are on-par or often better than conventional benchtop
techniques. Various microchip-based processes including sample filtration' 2, dilution3 4, mixing5,
polymerase chain reaction 6 7 , sample preconcentration- 0 and separation techniques6, 7 have been
demonstrated. The seamless integration of these functionalities into a single microchip platform have
enabled complex multi-step chip-based bioanalysis' such as immunoassays12' 13, DNA analysis 6'7' 14 and
chemical detection15' 16 to be performed from raw sample with minimal user intervention. These lab-on -
chip systems could change the current healthcare paradigm as sensitive tests could now be performed at a
doctor's office or from a portable device in resource-poor regions. Instant access to this important test
information would help healthcare providers in making a better diagnosis and prescribing the appropriate
treatment at much lower overall cost.
Aside from the versatile integration in lab-on-chip systems, microfluidic devices could make use
of the novel physics associated with the micro/nano structures to realize new capabilities. As we can now
fabricate structures with critical dimension comparable to biomolecules, we can directly manipulate
biomolecules based on their size-dependent interactions with the solid-state nanostructures. This had led
to applications such as biomolecular separation in nanochannel arrays 17-19 as well as ultrasensitive
biosensing using nanowires20' 21 and nanopores2225.Besides, interesting phenomena such as concentration
polarization at the micro-nano interface has been used successfully for sample preconcentration9 and
increasing the sensitivity of various biomarker assays26-28
1.2 New developments in biosensing
The sensitivity and application of biosensing depends critically on the methods used for detection. Thanks
to recent advances in material science, fabrication technology and discovery of new physics, several
notable ultrasensitive biosensors have been developed and reported in the literature. Enzyme-linked
immunosorbent assays29-31 (ELISA), which use enzymes-conjugated antibodies to continuously convert a
substrate to a detectable product, are still the gold standard in many assays such as detection of HIV due
to their high sensitivities. Other variants of ELISA, such as use of quantum dot-conjugated antibodies3,
polymerase chain reaction (PCR) amplification"3  and reduction of silver to enhance the output signal35'
14
36, have been demonstrated to detect target analytes with exquisite sensitivities. Ultrasensitive assays
using electrochemical stripping 7 also share some similarities with ELISA in using a built-in signal
amplification mechanism. There have also been several notable label-free detection methods including
platforms using silicon nanowires20, n, whispering-gallery mode optical sensors38, 39, suspended
microchannel resonator40' 4' and surface enhanced raman scaterring (SERS) 42. The common features
among these ultrasensitive assays are the various signal amplification mechanisms including
enzymatic/chemical amplification 9-37, field-effect enhancement20, n, as well as optical38, 39, 42 and
mechanical resonance 0' 41. These assays are also examples of heterogeneous assays, where the target
molecules are detected by selectively capturing them onto capture agents immobilized on a solid-phased
support. For portable lab-on-chip applications, heterogeneous assays present many challenges such as the
requirement for multiple washing steps and slow binding kinetics. Moreover, immobilizing specific
antibodies to the solid-phase support while maintaining the activity and specificity of the antibodies is a
non-trivial task and often a source of error in heterogeneous biosensors.
On the other hand, in homogeneous assays, no immobilization step is required as reaction
between the target molecule and capture agent is carried out in solution phase. Reacted molecules are
detected by a change in physical property such as fluorescence signal43 44, fluorescence polarization 44 ,
size-dependent light scattering4 , magnetic relaxation*6 and electrophoretic mobility47. Homogenous
assays are attractive from a point-of-care diagnostic viewpoint due to the fast reaction kinetics and simple
mix-and-use operation which does not require labor intensive washing steps. However, they are usually
less sensitive than their heterogeneous assay counterpart because of the lack of signal amplification. A
signal amplification method that could be generally applied to homogeneous assays would combine the
best of both worlds - ease of use of a homogeneous assay coupled with the sensitivity of a heterogeneous
enzyme-linked assay.
1.3 The issues of affinity capture agents
Due to their high affinity and specificity, antibodies have been used extensively as capture agents in
diagnostic tools48 . The use of antibodies in detecting analytes became widespread in the 1970s with
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polyclonal antisera derived from immunized animals. In 1975, the development of monoclonal antibodies
from hybridoma cells was a major milestone that allowed the production of a unique antibody in large
quantity49. Today, the antibody discovery process starts with immunizing an animal with the antigen of
interest over a course of several weeks, followed by isolating antibody-producing cells from the spleen of
the animal, fusing these cells with immortalized myeloma cells to form hybridoma cells, and finally
screening for cell lines that produce high affinity and specificity antibodies. These cells are continuously
cultured to harvest monoclonal antibodies. Due to the laborious process, identification and production of
antibodies could be very time consuming and expensive especially when searching for rare antibodies that
require screening of a large number of colonies. As such, this could lead to a prohibitively high cost when
using antibodies as affinity reagents. Furthermore, antibodies have limited shelf life and the performance
of the same antibody tends to vary from batch to batch. These are major roadblocks in developing robust,
affordable and standardized point-of-care diagnostic platforms.
Several alternative affinity capture agents, including oligonucleotide aptamers50 53 , phage-display
peptides54 and multiligand protein capture ligand55 , have been proposed to be replacements for antibodies
for diagnostic applications. Unlike antibodies, these capture agents are selected through in-vitro processes
such as phage display54, systematic evolution of ligands by exponential enrichment (SELEX) 56, and one
bead one compound (OBOC) method55 . Therefore, identification of a suitable capture agent is fast (days)
and miniaturization could further reduce the reagent cost. Due to the well defined chemical synthesis,
they could be produced with extreme accuracy and reproducibility, and various functional groups can be
attached to these molecules during synthesis. Finally, these synthetic capture agents are also more
resistant to denaturation and hence compatible with the use in point-of-care diagnostic devices. Compared
to antibodies, however, these capture agents often have lower binding strengths. This could limit their use
in heterogeneous assays, where stringent washing steps could detach the target molecules. Their lower
binding affinities also necessitate higher sensitivity methods to detect the comparatively lesser target
molecules that are bound at equilibrium.
1.4 Signal amplification in homogeneous assays
Signal amplification techniques are essential in order to boost the sensitivities of biosensors to detect low
abundant analytes. This aspect is especially important in portable lab-on-chip systems where the optical
path length is short and when the integrated detection system has limited sensitivity. ELISA or other
chemical amplification techniques can be routinely implemented in heterogeneous assays, but it is much
more challenging to achieve this in homogeneous assays.
There have been a few reports of enzyme amplification in homogeneous assays, such as the
enzyme-multiplied immunoassay technique (EMIT)57, enzyme channeling5 8  and enzyme
complementation immunoassay59. These techniques are based on the principle that when the target
molecule binds to the enzyme-linked antibody, the enzyme activity is altered due to steric effects. Such
altered activities can be read out via observing the accumulation of reaction products, as in ELISA.
However, since these assays are based on changes in the three-dimensional conformation of the enzymes
upon target binding, considerable amount of selection and optimization is required to identify the
effective capture agent conjugate for each target. Therefore, they are seldom used in real applications.
Physical (instead of enzymatic or chemical) signal amplification methods have also been
demonstrated in the context of homogeneous assays. These are usually achieved by concentrating
molecular probes/substrates which undergo fluorescence change upon reaction with the target. Examples
include electrokinetic concentration of special substrates for proteases27 and kinases 60 which become
fluorescent upon reaction with their target molecule, as well as isotachophoresis concentration of
molecular beacons which undergo strong fluorescence enhancement upon binding to a target RNA61.
Physical signal amplification in these cases greatly improved the sensitivities of each assay. Nevertheless,
it should be noted that the molecular probes/substrates for these assays are specially customized and
designed for detection of these target molecules. It is an exception rather than a norm that such probes are
available for a given target molecule.
Another strategy for amplifying signal in homogeneous assay is to preconcentrate all the
biomolecules in the reaction mixture before separating them for detection. Unlike the above two classes
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of methods, these techniques can be applied to a very large class of assays as most biological reaction or
binding result in changes in size or charge that can be detected in a mobility shift assay. Various
preconcentration techniques such as membrane preconcentrations'6 , 6,3 field-amplified sample stacking
(FASS) 64, isotachophoresis (ITP)65 and electrokinetic trapping9 66 have been used in conjunction with
downstream electrophoretic separation to improve detection sensitivity. As the preconcentration and
separation steps were carried out sequentially in these methods, band dispersion and complex dissociation
during separation would ultimately reduce the sensitivity enhancement. Field gradient focusing methods
such as electric field gradient focusing (EFGF)67-69, bipolar electrode focusing70' 7' and temperature
gradient focusing (TGF)7 2-75 are able to simultaneously concentrate and separate analytes of different
mobilities. However, these techniques involve the use of special buffers, electrodes in microchannels that
cause bubble generation, complicated temperature control setups and nonstandard fabrication.
Furthermore, most of these techniques were only demonstrated for concentration and separation of model
fluorescent protein and not for real biological assays. Therefore, despite many efforts, there is still no
general platform that can be used to provide signal amplification in homogeneous assays.
1.5 Thesis outline and scope
The lack of amplification method in homogeneous assays is a bottleneck that limits their use for sensitive
measurements. In recognizing the comparative advantages of homogeneous assays over heterogeneous
assays for lab-on-chip systems, we aimed to increase the sensitivities of homogeneous assays by
implementing physical signal amplification methods. In this thesis, we have developed two different
techniques to simultaneously concentrate and separate reacted from unreacted target molecules by
electrophoretic mobility and size differences. The general applicability of these platforms for point-of-
care diagnostics is demonstrated in the context of improving the sensitivity of aptamer-based affinity
probe electrophoresis assay and homogeneous iminunoassay for clinically relevant biomarkers. Finally,
we show that this homogeneous amplification platform is a powerful tool that enables measurements of
biological activities in single cells that were previously very difficult to obtain.
Electrophoretic mobility shift assays are the workhorse of molecular biology and have been
widely used to measure various biomolecular interactions and enzymatic reactions. In Chapter 2, we
developed a microfluidic electrokinetic concentration device to realize a continuous signal amplification
scheme for homogeneous mobility shift assays. This is demonstrated in the context of an electrokinetic
concentration-enhanced aptamer affinity probe electrophoresis assay to achieve highly sensitive and
quantitative detection of protein biomarkers. We reported the lowest detection limit for two biomarkers,
human immunoglobulin E (IgE) and human immunodeficiency virus 1 reverse transcriptase (HIV-1 RT),
in a multiplexed mocrofluidic platform using low voltages and gravitational induced flow without the
need of periphery equipments (syringe pumps, temperature blocks) or multiple buffers. This work is
timely and impactful because it directly addresses the sensitivity shortcomings of using aptamers as low
cost and robust substitutes for antibodies in point-of-care applications.
There are some cases where biomolecular interactions do not lead to an appreciable mobility
change. In those instances, a size difference between reacted and unreacted biomolecules can often be
used as a measure for the degree of interaction. In Chapter 3, we developed a herringbone nanofilter array
which allows continuous flow size-selective concentration of biomolecules. This is enabled by precise
microfabrication of solid-state nanostructures that facilitates size-dependent interactions with
biomolecules with comparable critical dimensions. As a proof of concept, we demonstrated the utility of
this platform to perform a sensitive homogeneous immunoassay for C-reactive protein, a biomarker for
cardiac disease, at clinically relevant concentrations. The continuous flow format also makes this device
an attractive sample preparation tool to continuously purify and concentrate target molecules based on
size from a sample before performing downstream analysis.
In Chapter 4, we explored how we could adapt the concentration-enhanced mobility shift assay
platform developed in Chapter 2 as a tool for basic biological studies. Kinases are important enzymes in
the cellular signaling pathways that affect cell fate, yet little is known about how individual cells in
different states of intracellular processing respond differently to external stimuli, since most conventional
techniques provide only a population-averaged measurement of the signals within the regulatory pathway.
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A platform technology that can reliably assay for kinase activity from single cells is a valuable tool for
biologists to study how individual cells develop into different cell fates and correlate with their
phenotype. In Chapter 4, we first outlined the use of concentration-enhanced mobility shift assay platform
to measure cellular kinase activity with high sensitivity. We also developed a new capability to separate
multiple species in the concentration-enhanced mobility shift assay platform by using ampholytes or
rational design of peptide substrate and spacers. This capability enables users to perform multi-kinase
profiling using different substrates. To enable single cell kinase assay, we have developed technology to
first grow, isolate and observe single adherent cells, followed by parallel cell lysis and enzyme reaction in
confined nanoliter chambers, and lastly methods to recover reaction products and transfer to a separate
chip for analysis. By combining these methods, we demonstrated kinase activity assay with single cell
sensitivity and resolution. We also demonstrated multiple-kinase activity assay from single cells that
could provide vital clues about the functional relationships between different pathways in the signal
transduction network.
Finally, Chapter 5 summarizes the thesis contribution and presents future directions.
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Chapter 2
Concentration-Enhanced Mobility Shift Assay Platform for
Aptamer-Based Biomarker Detection
In this chapter, we describe a continuous signal amplification scheme for homogeneous mobility shift
assays. This is achieved by simultaneously concentrating and separating bound and unbound molecules
(with different electrophoretic mobilities) in a microfluidic device. The utility of this platform is
demonstrated in the context of an electrokinetic concentration-enhanced aptamer affinity probe
electrophoresis assay to achieve highly sensitive and quantitative detection of protein biomarkers. The
key weaknesses of aptamer as a binding agent (weak binding strength/fast target dissociation) were
counteracted by continuous injection of fresh sample while band-broadening phenomena were minimized
due to self-focusing effects. Within 30 minutes of continuous signal enhancement, we can detect 4.4 pM
human Immunoglobulin E (IgE) and 9 pM Human Immunodeficiency Virus 1 Reverse Transcriptase
(HIV-1 RT), which are among the lowest limits of detection (LOD) reported. IgE was detected in serum
sample with a LOD of 39 pM due to nonspecific interactions between aptamers and serum proteins.
2.1 Aptamers as affinity agents in diagnostics platforms
The issue of affinity agent is a bottleneck in developing robust, affordable and standardized diagnostic
platforms. For decades, antibody-based immunoassays have been used for disease diagnosis that requires
highly specific and sensitive recognition elements. However, production of antibodies is an expensive and
laborious process that involves immunizing host animals and developing hybridoma cell lines. Antibodies
are also prone to denaturing at ambient conditions and often subjected to batch-to-batch variations, thus
complicating their use in point-of-care diagnostic platform.
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Thrombin binding aptamer: 5'-GGTTGGTGTGGTTGG-3'
Figure 2.1: a) Schematic model, and b) 3-dimensional structure of the thrombin binding aptamer. The
highlighted bases form the G-quadruplex secondary structure. (Adapted from works of Schultze et al.1)
Recently, aptamers are emerging as an increasingly popular alternative to antibodies as affinity
probe in analytical applications. Aptamers are single-stranded oligonucleotides that have undergone
multiple round of in vitro selection to bind specifically to various molecular targets2' ". Figure 2.1 shows
an example of a 15 base pair DNA aptamer with secondary G-quadruplex structures that binds to human
thrombin protein'. As binding agents, aptamers can rival antibodies in terms of sensitivity and selectivity.
A major advantage of aptamers compared to antibodies is the low cost, since aptamers are synthesized
chemically whereas antibodies are produced from animals or hybridoma cell lines4. Unlike protein-based
binding agents, aptamers can also be stored in harsh environment without permanently denaturing4.
Finally, various functional groups can be easily attached to aptamers during synthesis with excellent
batch-to-batch uniformity. With these features, aptamers are very attractive candidates for developing
point-of care biosensors. Recently, more than 800 aptamers have been generated against proteins that are
potential biomarkers5. These are promising signs that aptamer biosensors will find widespread
applications.
Various kinds of aptamer-based biosensors, both homogeneous and heterogeneous assays, have
been reported in the literature. In heterogeneous assays, aptamers are immobilized on a solid surface to
selectively capture target molecules from the sample. These include electrochemical assays6, 7 and
sandwich assays8 where the captured target protein is detected by a secondary fluorescent or enzyme
labeled aptamer. Label-free detection is also possible with surface-plasmon resonance9'10 or quartz crystal
microbalance" techniques. On the other hand, aptamers and target molecules react in solution phase in
homogeneous assays. These include assays using structure-switching aptamers that change fluorescence
when they bind to the target12' 13, electrophoresis based methods which can separate bound and unbound
aptamers14 15 , and techniques which rely on polymerase chain reaction (PCR) such as proximity ligation
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assays
Comparing between heterogeneous and homogeneous aptamer biosensors, the heterogeneous
aptamer assays are usually very sensitive because the signal can be amplified by enzymes. However,
these sensors require multiple washing steps and binding kinetics of target molecules to surface bound
aptamers is slow. There is also potential loss of aptamer binding activity after surface immobilization and
the inherent difficulty of generating two aptamers against distinct epitopes on a target biomarker to be
used in a sandwich assay format. On the other hand, the homogeneous assays are very easy to use and
have fast binding kinetics, but usually have lower sensitivity and many of the structure-switching type
assays require customization for each aptamer-target binding pair. The homogeneous aptamer assays are
attractive candidates as point-of-care biosensor platforms because they are fast and simple to use.
However, the bottleneck that prevents their widespread application is the limited sensitivity. A general
signal amplification scheme that can increase the sensitivity of homogeneous aptamer assays would
greatly expand their utility.
2.2 Electrokinetic concentration as a signal amplification module for aptamer affinity
probe electrophoresis assay
Among the homogeneous aptamer biosensors, capillary electrophoresis (CE) based methods which can
separate bound and unbound aptamers have been widely used to detect specific target proteins such as
IgE 4 - 17, 18, thrombin 4' "Q, ricin5 , and HIV-1 reverse transcriptase (HIV-1 RT)17 , 20, 21. Unlike
heterogeneous immunoassay methods such as ELISA that require several hours and multiple washing
steps, the homogeneous CE assay is performed in one step with only a short incubation time ( 30
minutes). However, CE assays are generally less sensitive than ELISA due to the ability of enzymes in
ELISA to continuously convert a substrate to visible product over time. Furthermore, band dispersion and
complex dissociation when using lower affinity (high Kd) aptamers limits their applicability to detect low
abundance biomarkers.
As described in Chapter 1, the readout sensitivity of homogeneous assays can be improved by
physically preconcentration. In the context of aptamer-based CE analysis, sample preconcentration has
been reported in the forms of sample sweeping'9, preconcentration using a size-exclusion membrane8 ,
transient isotachophoresis (t-ITP)22, and temperature gradient focusing (TGF)23 . Preconcentration and
separation were carried out sequentially in the first two cases, thus the detection sensitivity was limited by
band-broadening during the separation step. The t-ITP method required multiple buffer arrangements and
concentration factor was limited by injected plug volume. In the TGF example, special temperature
sensitive buffer was needed and higher limit of detection (LOD) was expected since detection was based
on monitoring a small decrease in the large free aptamer peak. In all these examples, high voltages of >
1kV are required.
The Han group has previously reported on nanofluidic electrokinetic concentration devices that
can continuously collect negatively charged molecules in a given sample into a much smaller volume,
thereby increasing local concentration significantly24. Electrokinetic concentration is particularly
amenable to lab-on-chip applications as it has been demonstrated to accomplish very high concentration
factors and does not require complicated setup such as high voltage, multiple buffer arrangements and
temperature control schemes. This principle has been used successfully in several approaches to realize
ultra-high sensitivity immunoassays. In the first instance, by using an electrokinetic concentrator to
increase the local concentration of target molecules around antibody-conjugated beads, the primary
immunobinding kinetics and assay sensitivity are greatly improved. In another method, an electrokinetic
concentrator is used to enhance the readout sensitivity of ELISA by accumulating the fluorescent turnover
products from target-bound enzymes26 . Both these platforms, however, are examples of heterogeneous
immunoassays. Continuous physical amplification for homogeneous binding assays has not been
demonstrated to date as it would require the additional capability of separating bound from unbound
analytes in solution phase at the same time.
In this chapter, we describe an electrokinetic concentration device that can simultaneously
concentrate and separate biomolecules based on mobility differences. This device is used to improve the
sensitivity of an aptamer affinity probe electrophoresis assay. This scheme features three simultaneous
processes: 1) continuous injection, 2) focusing, and 3) separation of the free aptamers and aptamer-protein
complexes. One of the significant disadvantages of aptamer affinity probe CE is that complex may
dissociate during long migration times, leading to weak or even absence of signal 27. Decreasing the time
spent on column, either by applying very high electric fields or utilization of hydrodynamic flow was
often necessary to achieve reliable detection of the aptamer-protein complex 27. In this new scheme, we
counteract dissociation of the aptamer-protein complex by continuous injection and accumulation of fresh
sample from the inlet reservoir. Band broadening phenomena commonly encountered in CE are also
minimized due to the self-focusing effect. When a continuous flux of sample from the equilibrium
mixture in the reservoir is subjected to simultaneous focusing and separation the signal-to-noise ratio
increases with time. A good signal enhancement scheme is the key to highly sensitive assays such as
ELISA. The scheme presented here presents an opportunity to enhance the signal in homogeneous
mobility shift assay for better sensitivity.
As a proof of concept, we demonstrate the use of electrokinetic concentration-enhanced aptamer
affinity probe electrophoresis assays for two different disease biomarkers, namely human
Immunoglobulin E (IgE) and Human Immunodificiency Virus 1 Reverse Transcriptase (HIV-1 RT). IgE
is the least abundant class of antibodies produced in human, and plays an important role in generating
allergic response as well as defending against parasites 28, 29. Some recent studies have suggested the use of
serum IgE as a predictive biomarker for diseases such as asthma and peanut allergy, 30. On the other
hand, HIV-1 RT is a key diagnostic and therapeutic target of HIV- 133. Many aptamer based sensor have
been used to detect IgE with different LOD, these include methods based on fluorescence enhancement
(57 pM) 3, carbon nanotube field effect transistors (250 pM)35 , surface plasmon resonance (18.5 pM) 10,
CE (46 pM)' 4' 17. 18 and aptamer microarray using labeled IgE (10 pM)3 6, 37. Meanwhile, for detection of
HIV-1 RT, the methods reported are predominantly based on CE (100 pM)17' 20, 21, temperature gradient
focusing (84 pM), transient isotachophoresis (<1pM) and CE followed by PCR (30 fM). It is worth noting
that the LOD reported is dependent on detection instruments and the affinity of the particular aptamers,
and that coupling separation with amplification step often leads to dramatic increase in sensitivity.
Using our platform, we obtained LOD of 4.4 pM and 9 pM for human IgE and HIV-RT
respectively in simple buffer after 30 minutes preconcentration, compared to LOD of 46 pM14 and 100
pM'7 obtained with conventional CE methods. These are the lowest assay LOD reported in the literature
for aptamer affinity probe capillary electrophoresis in spite of the inferior detector used for our assays (arc
lamp and CCD camera) versus Laser Induced Fluorescence and Photomultiplier Tube for CE. To
demonstrate the applicability of this assay to complex sample analysis, we performed the assay in 10-fold
diluted donkey serum. Initial experiments showed significant nonspecific interaction between DNA
aptamers and serum proteins. However, we found that addition of nonspecific and nonfluorescent
oligonucleotides largely suppresses the matrix interference, thus enabling us to detect IgE in 10% donkey
serum with a LOD of 39 pM.
2.3 Principle of the assay
Figure 2.2 shows the key operation of the poly(dimethylsiloxane) (PDMS) microfluidic electrokinetic
concentration chip. The basic device consists of two microchannels connected by a cation selective
channel that allows the flow of positively charged ions (cations) but impedes the flow of negatively
charged ions (anions). Cation selective channels in microfluidics systems have been realized in the form
of glass nanochannels where the overlap between Debye layers can exclude coions, or in the form of ion-
selective membranes such as Nafion where the presence of highly negatively charged chemical side
groups strongly impedes the flow of anions. Under the voltage configuration shown in Figure 2.2a,
cations can electromigrate from the top to bottom microchannel, but the passage of anions from the
bottom to top microchannel is blocked. As a result, a region depleted of both anions and cations is created
in the top microchannel at the vicinity of the cation selective channel in a process known as concentration
polarization. The conductivity gradient at the boundary of the ion depletion zone gives rise to a stable
electric field gradient. When a sample is injected into this microchannel with a constant bulk flow (due to
hydrodynamic pressure or electroosmotic flow), the negatively charged biomolecules will experience an
opposing electromigration velocity proportional to the electric field and their electrophoretic mobilities.
As shown schematically in Figure 2.2b, the biomolecules stop moving and focus at the location where
the electrophoretic velocity balances the bulk velocity. Free aptamers, which have very high
electrophoretic mobilities due to the highly negative-charged backbone of the oligonucleotide, are
concentrated at the low electric field region. On the other hand, the aptamer-protein complex has a lower
mobility due to its larger mass; therefore it concentrates nearer to the cation selective membrane where
the electric field is higher. In this way, bound and unbound aptamers can be simultaneously separated and
concentrated to facilitate sensitive measurement of the target protein in the sample.
Conventional aptamer affinity probe CE operate in a nonequilibrium condition, since there are no
targets in the run buffer that allow for rebinding of aptamers that have dissociated from their initial target
during separation. A unique advantage of this platform is that the free target protein molecules are able to
travel downstream beyond the concentrated aptamer-protein complex band (an even higher electric field
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is needed to stop the low mobility free protein). Therefore, aptamers that have dissociated from their
target in the complex band can quickly rebind with free proteins in the run buffer and regenerate the
complex, akin to the Equilibrium Capillary Electrophoresis of Equilibrium Mixtures (ECEEM) 38 where a
plug of equilibrium aptamer-target mixture is injected and separated in a capillary prefilled with target.
This is an important advantage which allows even aptamers with relatively high Kd's to be used in this
platform with good sensitivity. Using this device, we realized a multiplexed microfluidic platform where
homogeneous aptamer affinity probe electrophoresis assays can be performed with low voltages (30V)
and gravitation-induced flow without the need of periphery equipments (syringe pumps, temperature
blocks) or multiple buffers.
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Figure 2.2: a) Ion selective membrane creates a local ion depletion zone with high electric field upon
applying a voltage, b) Free aptamers and aptamer-protein complex concentrate at different locations on
the electric field profile due to their different electrophoretic mobility, c) Optical image of multiplexd
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2.4 Experimental section
2.4.1 Reagents and chemicals
Unless stated otherwise, all chemicals used in the experiments were purchased from Sigma (St. Louis,
MO). Human myeloma IgE was purchased from Athens Research and Technology, Inc. (Athens, GA).
Recombinant HIV-1 reverse transcriptase (HIV-1 RT) was purchased from Worthington Biochemical
Corporation (Lakewood, NJ). Oligonucleotides were synthesized and fluorescently labeled by Integrated
DNA Technologies, Inc. (Coralville, IA). IgE -binding aptamer (5'-GGG GCA CGT TTA TCC GTC
CCT CCT AGT GGC GTG CCC C-3') was labeled with 6-carboxyfluorescein (FAM) during synthesis at
the 5' end using ethylene glycol linker 4 . HIV-I RT-binding aptamer (5'-AT CCG CCT GAT TAG CGA
TAC TCA GAA GGA TAA ACT GTC CAG AAC TTG GA-3') was labeled directly at the 5' end with
FAM17. Nonfluorescent nonspecific oligonucleotides (5'-TGG TCT TGT GTG GCT GTG GCT ATG
TCT GAT CTT AAT CCA CGA AGT CAC C-3')17 were also obtained from the same source. Donkey
serum was purchased from Innovative Research (Novi, MI). All solutions were made with deionized
water (18.2Mg) by Fluid Solutions (Lowell, MA).
2.4.2 Microchip fabrication
The microchip was fabricated using poly(dimethysiloxane) PDMS (Sylgard 184, Dow Corning Inc.,
Midland, MI) irreversibly bonded on a glass slide. Microchannels were molded in PDMS by replica
molding technique16 . To obtain the positive master mold, the desired design was photolithographically
patterned onto a silicon wafer using positive photoresist. Next, the wafer was etched to a depth of 6 tm
via a reactive ion etching (RIE) process. The silicon master was further treated with trichlorosilane
(T2492, UCT Specialties, Bristol, PA) in a vacuum desiccator overnight to prevent adhesion to PDMS.
We fabricated the ion-selective nanoporous structures by using the microflow patterning
technique to obtain a thin strip of Nafion film on a standard glass slide7 ' 18. A 50 prm deep and 200 prm
wide PDMS microchannel was used to define the flow path of the Nafion solution (20 wt% solution in
lower aliphatic alcohol/H 20 mix, Sigma Aldrich, St. Louis, MO). The PDMS chip with microchannels
was irreversibly bonded on top of the glass slide by standard plasma bonding.
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Figure 2.2c showed the top view of the actual PDMS device used in the experiments. 0.1-10 gL
pipette tips (USA Scientific, Ocala, FL) were cut at the tip end with a razor blade and inserted into the
punched PDMS holes to act as fluid reservoirs. There were five separate inlets connecting to one outlet,
allowing five samples to be preconcentrated simultaneously. Two side channels flanked the inlet channels
to provide symmetrical electrical ground. The ion-selective nanojunction was fabricated at the center of
the device to concentrate sample molecules by electrokinetic trapping when voltages are applied. The
channels were filled with dyed solution for visualization purpose.
2.4.3 Microchip operation
Before the experiment, the PDMS device channels were passivated with 1% bovine serum albumin (BSA)
for 10 minutes to reduce nonspecific binding of the sample to channel walls. After that, the channels were
flushed with DI water 3 times and filled with buffer solution (10 mM Tris-HCl, pH 7.4) until the samples
were ready to be loaded. Sample was prepared by mixing 5 nM of fluorescently labeled aptamer with
different concentrations of analyte in buffer solution (10 mM Tris-HCl, 1 mM MgCl 2, 200 gg/mL BSA,
pH 7.4 (IgE)/ pH 8(HIV-1 RT)).
After 30 minutes incubation at room temperature, 30 pL of sample was loaded into each of the
five inlet reservoirs and drawn into the microchannel by applying a brief suction at the outlet reservoir.
The liquid height difference between the inlet reservoir and the empty outlet reservoir caused a well-
controlled gravitational flow of sample solution from inlet to outlet, without any need for external pump.
Electrodes were inserted into the inlet and buffer reservoirs on the chip and connected to a power
supply (Stanford Research Systems, Sunnyvale, CA). To initiate the concentration-enhanced affinity
probe electrophoresis assay, we applied 30 V at the inlet reservoirs while grounding the side channels. An
ionic concentration gradient was induced near the ion-selective membrane by concentration polarization
effect. Meanwhile, charged sample molecules are continuously separated and stacked at the location
where its electrophoretic velocity equals the bulk flow velocity. Within the experimental duration of 30
minutes, the fluorescent intensity of the stacked molecules increases linearly with time while background
noise remained constant, resulting in a high signal-to-noise ratio. To study the reproducibility of the
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assay, we repeated the experiment in the same device after removing the contents in the inlet reservoirs
and replacing them with new samples.
2.4.4 Measurement instrument and image analysis
An inverted epifluorescence microscope IX 71 (Olympus, Center Valley, PA) equipped with a cooled
CCD camera (SensiCam, Cooke Corp., Romulus, MI) was used for fluorescence imaging. A mechanical
shutter which only opens for 100 ms every 5 s when images are taken was used to prevent photobleaching
of the fluorescent molecules. The images were analyzed using the NIH ImageJ software. Flat-field
correction was performed by dividing a reference image of the device taken before each experiment.
Concentrations of bound and unbound aptamers were assumed to be directly proportional to the focused
peak height as demonstrated in previous work. Complex peak heights are normalized by the sum of
complex peak height and free aptamer peak height. Dose response curves were fitted using a four-
parameter logistic model. Origin 7 software (OriginLab Corp., Northampton, MA) was used for curve
fitting.
2.5 Optimization of assay
We first determined the optimal conditions that promote stable aptamer-protein complex formation in free
solution. The presence of divalent cations such as Mg2 has been reported to be necessary for certain
aptamer-protein complex formation39 . Without Mg 2 , no aptamer-IgE complex was formed while the
aptamer-HIVRT complex band was only weakly fluorescent. Addition of 1 mM of MgCl 2 greatly
improved the interaction between the species. We have also found that complex stability is a sensitive
function of buffer pH. Best results were obtained in 10 mM Tris-HCl buffer at pH 7.4 and pH 8.0 for IgE
and HIV-1 RT assays respectively.
In initial experiments, aptamer and target proteins (IgE and HIV-1 RT) were simultaneously
concentrated and separated in bare PDMS-glass devices. We observed no complex bands until high
concentrations (> 10 nM) of target proteins are added. Precoating the microchannels with 1% BSA for 10
minutes enabled us to clearly visualize the complex band corresponding to 750 pM of IgE (Figure 2.3a),
suggesting that prevention of nonspecific adsorption of proteins to the microchannel surface is important
to increase sensitivity. Precoating microchannel with 5% BSA did not lead to additional improvement in
sensitivity. Interestingly, as shown in Figure 2.3, adding BSA into the sample increases sensitivity of the
assay. Adding 50 tg/mL of BSA led to a clear complex band corresponding to 75 pM of IgE, while
addition of 100 tg/mL of BSA to the sample enabled detection of 7.5 pM of IgE. No further sensitivity
improvement was obtained when more than 200 4g/mL of BSA was added to the sample. Similar trends
were observed with the HIV-1 RT assays. This observation is thought to be due to BSA stabilizing the
aptamer-protein complex. Based on previous reports, it has been suggested that the presence of BSA in
solution helps maintain the correct aptamer and target protein conformation for optimal binding40 .
Presence of BSA in the solvent could also maintain the ratio of hydrophobic and hydrophilic regions on
the target protein, thus preventing it from denaturation 1 . Both the IgE and HIV-1 RT specific aptamers
did not interact with BSA, as the negative controls containing BSA but no target proteins did not form a
visible complex band. In all our subsequent experiments, the microchannel surfaces were passivated with
1% BSA for 10 minutes and 200 gg/mL of BSA were added to the samples to obtain the best sensitivites.
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We also observed that the separation distance between the bound and free aptamers increased
with the addition of high concentrations of BSA into the sample. We believe that this is due to an
isotachophoresis-like effect where preconcentration of an intermediate mobility species (BSA) results in a
broadening electric-field plateau that separates the bound and unbound aptamer bands42 . This suggests a
method whereby the separation resolution between two species can be independently tuned by adding a
spacer molecule with intermediate mobility in the sample.
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Figure 2.3: Addition of BSA improved detection of IgE in buffer using concentration-enhanced aptamer
affinity probe electrophoresis assay. a) no BSA in sample (cannot detect 75 pM IgE), b) 50 pg/mL BSA
in sample (can detect 75 pM IgE), c) 100 ptg/mL BSA in sample (can detect 7.5 pM IgE).
2.6 Detection of IgE and HIV-1 RT from buffer
We first demonstrate electrokinetic concentration-enhanced affinity probe electrophoresis assay of IgE
using a specific aptamer for this protein. Upon binding to IgE, the mobility of a free aptamer (-2.81 X 10-4
cm2 V-1 s-) is expected to shift to -0.58x 104 cm 2 V-1 S-i 17. Figure 2.4 shows the representative results for
electrokinetic concentration-enhanced affinity probe electrophoresis assay for human IgE using anti-IgE
aptamer as affinity probe. Experiments were performed in optimized buffer conditions (10 mM Tris-HCl,
pH 7.4, 1 mM MgCl 2, 200 pg/mL BSA) with constant aptamer concentration (5 nM) and varying
concentrations of human IgE protein (5 pM to 75 nM). During the 30 minutes experiment, the fluorescent
intensity of the bands increased linearly with time and achieved concentration factors of >1000. The
aptamer and complex bands were well-resolved (resolution-3.9). The position of the aptamer-protein
band was also remarkably stable; moving less than 200 iim after it reached an equilibrium position at
around 2 minutes. Slight variations in the band locations are due to differences in gravitation-induced
flow, but the ratiometric assay results are relatively insensitive to the exact band locations. As expected,
with increasing target protein concentration, the free aptamer peak decreased and the complex peak
increased. Figure 2.5b shows the aptmer-protein complex peak due to 4.92 pM of IgE. For comparison,
no complex band was observed in the negative control experiment.
The full dynamic range of the assay is shown in Figure 2.5c. The dose response curve was fitted
using the four-parameter logistic model. The average and standard deviation of the zero dose response
was calculated by performing two separate experiments where the sample contains no IgE, and taking the
peak ratios as described in the methods section. Figure 2.5d shows a linear relationship in the log-log plot
obtained at low IgE concentrations (5 pM - 7 nM). The LOD for IgE, calculated to be the analyte
concentration needed to produce a signal three standard deviations above the zero dose response, is 4.4
pM. This is the lowest LOD reported to date for detection of IgE using aptamers. Interestingly, the
apparent Kd (1.85 nM) is found to be more than an order of magnitude lower than the reported
dissociation constant for this aptamer (64 nM)14 . One possible explanation for this binding enhancement
is that aptamer-protein rebinding events in the electrokinetic concentration zone more than offset the
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effect of dissociation during the experiment. Given that aptamers generally have higher Kd compared to
antibodies, this scheme could significantly increase the sensitivity and utility of aptamer based assay.
Similar experiments were performed using Human Immunodeficiency Virus 1 Reverse
Transcriptase (HIV-1 RT) and an aptamer against this protein to demonstrate that this method is general
and can be applied to multiple analytes. Upon binding to IgE, the mobility of a free aptamer (-2.81 x10-4
cm2 V1 s-) is expected to shift to -0.50x 1 0 -4 cm2 V-1 S-1 14 17 .The results (Figure 2.6) showed a LOD of 9
pM, which is also among the lowest LOD reported to date for this aptamer-protein pair.
bFigure 2.4: Experimental results for multiplexed concentration enhanced aptamer affinity probe
electrophoresis assay for detecting a) high concentrations, and b) low concentrations of IgE in buffer
solution after 30 minutes of concentration.
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Figure 2.5: a) Electropherogram for optimized electrokinetic concentration and separation of IgE aptamer
(5 nM) and different concentrations of IgE: (1) 4.92 pM, (2) 0.6 nM, and (3) 6.75 nM IgE. The complex
band is labeled with an asterisk, b) Inset demonstrates detection of 4.92 pM IgE in buffer, c) Dose-
response curve of anti-IgE aptamer with IgE spiked in buffer, error bars represent standard error from
duplicate experiments, d) Linear relationship in the log-log plot is obtained at low concentrations of IgE.
The measured LOD is 4.4 pM IgE.
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Figure 2.6: a,b) Electropherogram demonstrating detection of 6.5 pM HIV-1 RT in buffer, c) Dose
response curve of anti-HIV-lRT aptamer with HIV-RT spiked in buffer, error bars represent standard
error from duplicate experiments, d) Linear relationship in the log-log plot is obtained at low
concentrations of HIV-lRT, measured LOD is 9 pM HIV-1 RT
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2.7 Detection of IgE from serum sample
To demonstrate the applicability of this assay to complex sample analysis, we performed the IgE assay in
a buffer that consists of diluted donkey serum. Initial experiments showed significant interactions of
serum components with the aptamers. Figure 2.7 showed a representative IgE assay performed in 1%
donkey serum. We observed fluorescent precipitation in the sample solution. Moreover, there is formation
of an extra fluorescent band in between the free aptamer and aptamer-protein band. Interestingly, the
extra band is well defined and baseline-separated from the other two bands. This suggests that the
aptamer is interacting with a particular species in serum, such as DNA binding proteins found in
mammalian serum43 . Although this interference did not interfere with the formation and determination of
the free aptamer and the aptamer-protein complex (they are all baseline separated), the fluorescent
precipitation in the sample solution caused large spikes in the electrophoregram.
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Figure 2.7: Concentration enhanced aptamer affinity probe electrophoresis assay for detecting IgE in
sample containing 1% donkey serum. Aptamer binding to serum components gave rise to a third
fluorescent band in between the free aptamer and aptamer-target protein band. Fluorescent precipitation is
also observed in solution.
It has been reported that serum matrix interference on aptamer affinity probe capillary
electrophoresis can be suppressed by addition of nonspecific oligonucleotides that bind competitively to
the interfering serum proteins"7 . We found that addition of 10 pM of a nonspecific and nonfluorescent 49-
mer oligonucleotide17 eliminated the extra band and fluorescent precipitation in a sample solution
containing 10% donkey serum.
Figure 2.8 shows the experimental results for IgE assay in 10% donkey serum after 1 minute
preconcentration, with addition of 10 pM of nonspecific oligonucleotide to suppress matrix interference.
Due to the high total protein concentration in the sample, preconcentration leads to a rapid broadening of
electric field plateau between the free aptamer and the aptamer-protein complex as discussed in the
previous section. We can only perform experiments for 2 minutes before the separation distance exceeds
the microscope field of view. Due to the shorter preconcentration time, there is less sensitivity
enhancement. We obtained a LOD of 39 pM for IgE assay in 10% donkey serum.
The LOD using this scheme is ultimately restricted by the specificity, rather than the affinity (Kd)
of the aptamers against the target protein. Experiments in the serum sample showed that two bands were
observed even in the case of the negative control (Figure 2.8b), which indicated that nonspecific binding
was not completely eliminated by addition of nonspecific oligonucleotides. On the other hand,
experiments in simple buffer showed that signal-to-noise ratio increased with time. We can obtain better
sensitivities at the expense of longer assay time. The key advantage of this technique is a continuous
influx of sample that counteracts the effects of dissociation and a self-focusing ability that minimizes
band dispersion, so even aptamers with relatively high dissociation constant can be used in this assay.
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Figure 2.8: a,b) Experimental results for multiplexed concentration enhanced aptamer affinity probe
electrophoresis assay for detecting IgE in 10% donkey serum, c) Dose response curve of anti-IgE aptamer
with IgE spiked in 10% serum, error bars represent standard error from duplicate experiments, d) Log-log
plot at low concentrations of IgE in serum showing effects of nonspecific binding on sensitivity. The
measured LOD is 39 pM IgE.
2.8 Summary
In conclusion, this chapter demonstrates the use of electrokinetic concentration to realize a continuous
signal amplification scheme that increases the sensitivity of homogeneous mobility shift assay. Aptamers
are attractive alternatives to antibodies for point-of-care diagnostics purposes due to their stability, low
cost, and homogeneity. Our aptamer based affinity probe electrophoresis assay in a lab-on-chip device
could detect 4.4 pM and 9 pM of IgE and HIV-RT in simple buffers, and detect 39 pM of IgE in 10%
serum sample. These are among the lowest LOD obtained for aptamer affinity probe capillary
electrophoresis experiments. Furthermore, this method has an advantage over many other assays since it
is rapid, uses low voltage, consumes very little sample, can be multiplexed, and is very user-friendly (no
multiple processing steps required).
Miniaturized capillary electrophoresis devices are one of the first microfluidic systems that
gained popular acceptance, and remains a mainstay in lab-on-chip platforms. The method presented in
this chapter has broad applicability to improve the sensitivity of various capillary electrophoresis assays,
such as those involving protein-protein interactions and enzymatic reactions.
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Chapter 3
Differential Concentration of Biomolecules using Herringbone
Nanofilter Array
*The work presented in this chapter was done in collaboration with Hansen Bow, who designed and
fabricated the devices
In Chapter 2, we have described a method whereby simultaneous focusing and separation of bound and
unbound molecules can lead to an ultrasensitive homogeneous aptamer-based biomarker detection
method. Separation of the analytes of interest is based on electrophoretic mobility difference, which is
significant when small, highly negatively charged aptamers bind to relatively larger target proteins. To
our knowledge, the method presented is the first reported signal amplification technique applicable to a
broad class of homogeneous electrophoretic mobility shift assays.
However, not all biomolecular interactions lead to detectable and predictable changes in their
electrophoretic mobility. For example, the free solution electrophoretic mobility of DNA is essentially
size independent2 , while the interactions of near-neutral biomolecules often result in negligible mobility
shifts. To extend the concept of signal amplification to a broader range of homogeneous biological assays,
we are also interested in exploring alternative physical principles that can lead to simultaneous
fractionation and concentration of analytes.
In this chapter, we introduce a microfabricated anisotropic sieving structure consisting of a
herringbone nanofilter array (H4NA). The structural anisotropy of the HNA causes different sized
biomolecules to follow different migration trajectory. In addition, the HINA also redirect large
biomolecules to focus at particular positions in the device, leading to continuous flow biomolecule
concentration. We will show how we make use of these phenomena to interrogate biomolecular
interactions, including protein-DNA binding, protein-protein interaction and antibody-antigen binding.
The final example demonstrates a novel method to perform homogeneous immunoassay for biomarker
detection at clinically relevant concentrations.
3.1 Nanostructures for biomolecular sieving
Standard techniques for biomolecular separation such as gel filtration chromatography and gel
electrophoresis rely on random polymer gels to provide nanometer-sized pores that are suitable for
molecular sieving. While gel-based systems are proven reliable, the separation resolution is poor in gel
filtration chromatography and sample recovery is difficult in gel electrophoresis. Extensive sample
preparation steps which involve expensive infrastructures and lengthy procedures are also required.
Furthermore, the considerably sample and reagent consumption in these traditional methods is a
bottleneck towards multiplexed measurements. These are formidable obstacles that limit their use in
point-of-care diagnostic settings.
Recent advances in micro- and nanofluidic technologies have opened up exciting opportunities in
sample preparation and analysis as they promise miniaturization, automation, low sample consumption
and seamless integration into a lab-on-chip format3 5 . For example, a recent integrated microfluidic
system6 has been demonstrated to perform on-chip blood separation and measurement of a dozen
biomarkers within 10 minutes from whole blood obtained from a finger prick. For on-chip biomolecular
separation, conventional microfluidic platforms use gelatinous sieving materials contained in microfluidic
channels7-9. However, these foreign sieving matrices pose intrinsic difficulties for the integration of the
separation process with the automated multistep point-of-care (POC) diagnostic platform. Furthermore,
additional steps are needed to remove the sieving material from the sample for downstream processing.
Over the last decades, there have been many efforts to develop regular nanofluidic structures as
an alternative to disordered gel material for biomolecule separation in microfluidic systems - . As we
can now fabricate nanofluidic structures with critical dimension comparable to biomolecules, we can
directly manipulate biomolecules based on their size-dependent interactions with the solid-state
nanostructures.
Various fabrication techniques for regular nanostructures have been explored, these include
bottom-up approaches such as self-assembled colloidal particle packing 1-1, ultra-thin porous
membranes16 and top-down approaches involving the use of semiconductor microfabrication tools to
1 , 1 1pattern nanostructures with precise control of channel dimensions", . Among these techniques, the
top-down approaches are easy to integrate with other microfluidic systems. They also offer tremendous
design flexibilities - by tailoring the shape and sizes of the nanostructures, we can exploit various
nanofluidic phenomena to achieve functionalities that would not be possible in macro- or even microscale
systems.
Microfabricated nanostructures that separate long DNA based on size have been realized in the
forms of pillar arrays that mimic gel fibers 9 .23 , channels with alternating deep and shallow regions that
act as entropic trap arrays17, 24, 25, and asymmetric obstacles that act as Brownian ratchet 26-2 9 . These
devices operate by either separating long DNA molecules based on their differences in conformational
entropy, or rectifying lateral Brownian motion to deflect biomolecules based on their diffusivity.
Separation of smaller molecules such as proteins and short oligonucleotides has also been demonstrated in
devices consisting of nanofilter arrays30 .3 1 However, the mechanism of separation is attributed to Ogston
sieving instead of entropic trapping for the case when the biomolecules are smaller than the nanopores.
Recently, a two dimensional anisotropic nanofilter array (ANA) device has been implemented for
continuous-flow separation of different sized DNA and protein 3. The designed structural anisotropy of
the ANA causes biomolecules of different sizes and charges to follow distinct trajectories, leading to
efficient continuous-flow separation. The continuous-flow operation of the ANA allows the separation
process to be performed in-line with other continuous-flow processes, thus facilitating the integration of
the separation step with upstream and downstream sample preparation or analysis steps. This unique
operational characteristic provides a great advantage over other microfluidic batch separation techniques
for the easy integration of the device into a common point-of-care diagnostic platform. As a step towards
this direction, this device has been utilized to perform quantitative analysis of disease-marker proteins by
continuously separating the larger antibody-protein immunocomplexes from the unbound antibodies32 .
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Finally, a method that continuously separate particles based on size using slanted obstacles in a
microchannel has been reported33 (Figure 3.1). The trajectory of the suspended particles is determined by
hydrophoresis, which is the movement of particles under the microstructure-induced pressure field.
Particle wall interaction will steer large particles with sizes comparable to the gap size of the slanted
obstacles to focus near the sidewall of the device. On the other hand, small particles follow the streamline
and exhibit a zig-zag trajectory motion, separate from the large particles. Using this method, the authors
completely separated polystyrene microbeads with 9 pm and 12 ptm diameters. In a separate paper, the
same authors demonstrated continuous separation of red blood cells and white blood cells population this
concept34. In a later paper, hydrophoretic separation of micron and submicron particles (0.5 pm - 1.1 gm)
and DNA molecules (radius of gyration 0.86 sm and 1.4 gm) was demonstrated using devices with
obstacle gaps down to 1.2 pm35 . DNA with radius of gyration greater than the obstacle gap had to change
their conformation to pass through the gap. Hence, unlike smaller DNA which could immediately pass
through the gap, they followed a different trajectory along the slanted obstacles until they acquire the
right conformation that allows them to enter the gap. This mode of sieving share some similarities with
the microfabricated entropic trap for long DNA separation17 , but the structural anisotropy (slanted
obstacles) enables continuous flow operation.
Slanted obstacle
Figure 3.1: a) Example of a hydrophoresis device that can continuously separate particles based on side
using slanted obstacles in a microchannel. b) Optical micrographs showing trajectories of 9 and 12 pm
beads passing 19 pm-height slanted obstacles at 0.1 ptL min-'. While the 9 pm bead was deviated from
the focused position (the lower side of the channel), the 12 pm bead stayed in the focused position.
(Adapted from works of Choi et al.")
3.2 Size based concentration of biomolecules using herringbone nanofilter array
In Chapter 2, we saw that coupling biomolecular concentration with the separation step could greatly
improve the assay sensitivity. The need for biomolecular concentration step is even greater in
micro/nanofluidic systems, where the low optical path length reduces detection sensitivity.
Conventionally, size-based concentration of biomolecules in microfluidic devices is achieved by trapping
large molecules in front of nanoporous gels and releasing them for analysis 36-39. These methods have
proven useful for increasing the assay sensitivity. However, as mentioned earlier, integrating foreign gel
material into microfluidic devices present fabrication challenges. Furthermore, these are batch processes,
which presents throughput and sample recovery challenges for downstream modules.
With the ability to fabricate nanochannels on the size order of biomolecules, one can
explore the possibility of continuously fractionation and concentration, utilizing the biomolecule-
nanofilter sieving interactions as a way to 'steer' molecules in a channel. In this section, we will
introduce the HNA device, which could differentially concentrate small biomolecules based on size. The
device consists of a periodic nanofilter array shaped like a herringbone (Figure 3.2a). The nanofilter
array has shallow regions with gap thickness of d, and deep regions with gap thickness of dd. The design
of the HNA device is similar to the periodic array of slanted obstacles used for hydrophoresis separation
of particles and long DNAs. However, the HNA device is designed to utilize a different sieving
mechanism (Ogston sieving)31. In the hydrophoretic separation of particles, the rotational flow induced by
anisotropic obstacles redirect different sized particles into different trajectory3 3 . For the separation of long
DNA, the obstacle gap size was smaller than the radius of gyration, and sieving involves molecules
deforming to pass through the gap35 . On the other hand, Ogston sieving is the relevant mechanism when
separating biomolecules whose sizes are smaller than the pore size in the herringbone nanofilter array.
Figure 3.2b illustrates the cross-section of the herringbone nanofilter array. An electric field
drives the movement of the biomolecules (electrophoresis or electroosmosis) through the shallow and
deep regions of the nanofilter array. Biomolecules experience a steric hindrance effect when they jump
across a nanofilter. Smaller molecules will have less resistance to jump across the nanofilter, thus will be
more likely to be driven to flow across the nanofilter array in a straight line (path of least resistance)
without altering their trajectory. On the other hand, larger sized biomolecules encounter a larger
configurational entropic energy barrier while they transition from the deep to shallow region31 , hence they
have less frequency to jump across the nanofilters and become more likely to be driven towards the center
of the herringbone structure. In this way, differently sized biomolecules are differentially concentrated in
a continuous flow manner.
The concentration ability of this device is achieved by the design geometry of the herringbone
nanostructure. The centerline of a herringbone structure represents a symmetric boundary condition, as
large molecules from both sides are directed towards the center. Under such circumstances, the center
region becomes a sink where large biomolecules accumulate. The only way for the trapped molecule to
exit the local sink is by jumping over the shallow region. The concentration factor of large biomolecules
in the center would be a function of its diffusion coefficient, trapping life time and the magnitude of the
forces that drive the molecules to the center. For the most effective Ogson sieving of biomolecules, we
should design the pore size to be comparable to the molecules to be analyzed4 0 . For the biomolecular
complexes that we are interested in (most oligonucleotides and globular proteins have radii of gyration
about 1-10 nm), we designed two depth for the nanofilter shallow region (53 nm and 80 nm) and the
corresponding depth for the deep regions are 80 nm and 173 nm.
One of the immediate applications for such a platform is the ability to perform rapid
quantification of biomarkers by separating free antibodies from the larger antibody-antigen complex.
In previous work the ANA is used for continuous flow size-based immunoseparation . However,
detection sensitivity is poor as molecular dispersion reduces the signal at the detection region. With the
concentration ability of the proposed device, we hope to improve the detection sensitivity by
homogeneous signal amplification. Another application that we envisioned for this platform is for sample
preparation, where we can simultaneously enrich and purify a target molecule based on size. As the
presence of high-abundance serum proteins (mostly albumin and immunoglobulin) present significant
limitation to biomarker detection specificity and sensitivity, size-based removal of these compound prior
to detection could improve the specificity and sensitivity of the assay. The continuous flow operation of
the proposed device is ideally suitable for point-of-care formats such as lateral flow immunoassays.
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Figure 3.2: a) Schematic of the HNA device consisting of periodic nanofilter array shaped like a
herringbone. An electric field drives the movement of the biomolecules through the nanofilter array. b)
Cross-section of the HNA device showing shallow regions with gap thickness of ds and deep regions with
gap thickness of dd. Small molecules (red) can migrate across the nanofilter array in a straight line without
altering their trajectory. Large biomolecules (green) encounter a larger configurational entropic energy
barrier while they transition from the deep to shallow region, hence they have less frequency to jump
across the nanofilters and become more likely to be driven towards the center of the herringbone
structure.
3.3 Device fabrication
The detailed fabrication process flow for this device has been reported elsewhere3 1. Briefly,
structural patterning and RIE etching is done on silicon wafer using a 3-mask process. A potassium
hydroxide etch was performed to etch a hole through the entire silicon wafer to create a buffer access
hold. After thermal oxidation to provide electrical isolation between the buffer and the conductive silicon
substrate, the herringbone nanofilter array was sealed by anodic bonding to a Pyrex wafer. A schematic of
the key steps in this fabrication process flow is shown in Figure 3.3.
1. RIE to define the depth of shallow region (1st mask)
2. RIE to define the depth of deep region (2"d mask)
3. KOH etching for buffer access hole (3rd mask)
4. Thermal oxidation to provide electrical isolation
Figure 3.3: Fabrication process of the herringbone nanofilter array device.
3.4 Concentration of short DNA molecules by Ogston Sieving
We first demonstrate concentration of short double stranded DNA in the herringbone nanofilter array.
Double stranded PCR markers (50-766 bp, New England Biolabs, Beverly, MA) was labeled with
YOYO-l intercalating fluorescent dye (Molecular Probes, Eugene, OR) with a dye to DNA base pair ratio
of 1:10. The final DNA concentration in the sample solution was 10 ptg/mL in 1 x Tris Borate EDTA
(TBE) buffer. Before the experiment, the device was equilibrated with the run buffer for 1 hour by
applying 100 V across the nanofilter array.
Figure 3.4 shows the experimental results in a d,= 53 nm device when the fluorescently labeled
PCR marker was injected. Since the DNA molecules were highly negatively charged, migration of
dsDNA followed the direction of electrophoresis. When 200 V was applied across the device, the DNA
molecules focused into a tight band in the center of the herringbone structure. This phenomena is
reversible, once the electric field is turned off, the focused band in the center of the channel quickly
disperse, resulting in a uniform fluorescence distribution in the entire device. The PCR marker contains 5
different DNA fragments of sizes ranging from 50 bp to 766 bp. Since the persistence length of DNA is
about 50 nm (about the contour length of 150 bp DNA), the PCR marker fragments are relatively
straight, rigid rodlike molecules with end-to-end distance of about 16 nm to 150 nm. As the shallow
region of the nanofilter is 53 nm, DNAs can enter these regions only in certain orientation. These
differences in configurational entropy between the shallow and deep region leads to Ogston sieving
effects41, 42. It is important to note that the smallest dimensions of these rod-like molecules are less than
the gap size of the shallow region, so the DNA molecules do not need to deform and change their
17, 43conformational entropy as in the entropic trapping regime for long DNA'
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Figure 3.4: Size based concentration of YOYO-l labeled PCR markers (50 - 766 bp) in the center of the
HNA device (d, = 53nm).
A potential application for this simple operation is to concentrate and focus DNA molecules from
a sample prior to launching them for electrophoretic sizing. By doing so, we can obtain
electropherograms with much higher signal and better resolution. Without any changes in process flow,
the herringbone nanofilter array could be implemented routinely as a sample preconcentration module
before size-based separation of biomolecules in the 1 -D nanofilter array. Finally, as a sample preparation
tool, this device can be used to continuously purify and concentrate the larger target molecules (e.g. DNA
and large proteins) from a sample before performing downstream analysis such as mass spectrometry.
Depending on the application, it is also possible to increase the throughput of these devices by creating
massively-parallel, ultra-high-aspect-ratio nanochannels as demonstrated previously'8 .
3.5 Differential concentration of DNA-protein complex
One class of important biomolecular interaction involves the binding of protein to DNA. In a cell, DNA-
protein interaction such as binding of transcription factors onto specific DNA sequences controls the
transcription of genetic information from DNA to mRNA. As described in Chapter 2, DNA aptamers that
can bind to specific target proteins are also recently gaining popularity for use in detecting and
quantifying biomarkers for clinical diagnostics"4.
The HNA device can be used as a platform to selectively concentrate larger DNA-protein
complex in a continuous flow manner and achieve rapid quantification of the target protein. To
demonstrate this, we performed experiment using biotinylated fluorescent single stranded DNA (15 bp,
Integrated DNA Technologies) which can bind to streptavidin (target protein). Figure 3.5 shows the
experimental results in a d, = 53 nm device. When 4 pM of the fluorescently labeled single stranded DNA
(ssDNA) in TBE 5x was injected, migration of ssDNA followed the direction of electrophoresis, but the
fluorescent profile in the HNA device appeared uniform. This is because the ssDNA is very small
(persistence length ~ 1.5 nm) compared to the size of the nanogap and Ogston sieving is not significant.
However, as shown in Figure 3.5b, when 2 ptM of the streptavidin was added to the DNA probes, we saw
a focused band in the center of the herringbone channel. Streptavidin is a globular protein (-3.5 nm) that
can bind a maximum of 4 biotin moieties, therefore the total size of the DNA-protein complex is about 8
nm. Ogston sieving could occur and lead to continuous concentration of larger DNA-protein complex.
Figure 3.5c shows the experimental results when the polarity of the electric field is reversed. Instead of
concentrating in the center of the herringbone nanofilter array, the DNA-protein complex now
concentrated at the sides of the nanofilter array as expected.
Although focusing of the DNA-protein complex was observed, the concentration factor was not
high. This is probably due to the relatively small size of the DNA-protein complex compared to the gap
height. Also, smaller molecules tend to have higher diffusion constant, which contributes to more
dispersion of the concentrated band. To optimize the performance of this assay, a nanofilter array with
smaller gap size should be used in the future. The ability to detect DNA-protein complex formation
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makes this device a useful tool to screen for transcription factors that bind to specific DNA sequences, or
to detect target proteins that bind to a specific aptamer. By virtue of the continuous flow operation of this
device, one could also envision using this to select and purify aptamers that bind to a target protein from a
DNA library by collecting the concentrated DNA-protein complex.
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Figure 3.5: Size based concentration of DNA-protein complex in HNA device (d, = 53 nm). a) Without
any target protein, the fluorescent DNA does not concentrate in the HNA device, b) Upon adding the
target protein, larger DNA-protein complex could concentrate in the center of the HNA device, c)
Reversing the electric field polarity cause the DNA-protein complex to concentrate at the side of the HNA
device.
3.6 Differential concentration of protein-protein complex
Protein-protein interactions that form complexes are important for the normal function of the cell. These
range from simple receptor-ligand binding to complicated multi-protein assemblies such as ribosomes and
proteosomes that perform essential cellular functions. Abnormal protein-protein interactions leading to
large protein complex formation could cause diseases such as Alzheimers and encephalopathies45 .
The herringbone nanofilter array is also capable of performing size-based concentration of protein
complexes under native conditions. As a proof of concept, we performed experiments using Alexa Fluor
488-conjugated streptavidin as a probe molecule to detect biotinylated BSA. The experiment is performed
using a ds = 80nm device in TBE 1 x buffer. In the negative control, the fluorescent streptavidin migrated
in the direction of electroosmosis but no concentration effect was observed due to its small size compared
to the nanogap. However, as we add in the target protein, we observe a brighter band in the center of the
channel, due to concentration of the larger streptavidin-biotinylated BSA complex (Figure 3.6a). Figure
3.6b is a plot of the fluorescence intensity profile across the herringbone nanofilter array for experiments
with different concentrations of biotinylated BSA while the concentration of the fluorescent streptavidin
probe molecule is kept constant at 20 pg/mL. The dose response curve in Figure 3.6c shows that the
fluorescence peak height of the concentrated complexes initially increases with the addition of the target
molecules, but when the target molecules are beyond a certain concentration, the fluorescence peak height
starts to decrease. This is the well known high-dose Hook effect4 6 . When the concentration of the target
molecules overwhelms the probe molecule, all the binding sites of the probe molecules are saturated and
large complexes cannot form. The point when maximum large complex is formed is known as the
equivalence point.
Figure 3.7 shows the experiments conducted in the same device with reversed electric field
polarity. Instead of concentrating at the center of the herringbone nanofilter array, the protein-protein
complexes focused near the sides of the nanofilter array. The dose response curves are similar for both
cases. Quantitative detection of the target protein is possible in both device configurations.
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Figure 3.6: Size based concentration of protein-protein complex under native conditions in HNA device
(ds = 80nm). a) Experimental results showing behavior of protein-protein complex in HNA device at
different target protein concentrations. b) Fluorescent intensity profile of the focused molecules at
different target protein concentrations. c) Maximum peak height vs target protein concentration.
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Figure 3.7: Size based concentration of protein-protein complex under native conditions in HNA device
(d, = 80 nm) under reversed electric field polarity. a) Experimental results showing behavior of protein-
protein complex in HNA device at different target protein concentrations. b) Fluorescent intensity profile
of the focused molecules at different target protein concentrations. c) Maximum peak height vs target
protein concentration.
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3.7 Differential concentration of antibody-antigen complex
Finally, we demonstrate the utility of the herringbone nanofilter array to perform a homogeneous
immunoassay. Owing to their high sensitivity and specificity, immunoassays have been widely employed
for clinical diagnostics and biochemical studies. Most of the common immunoassays feature a
heterogeneous format, where antibodies are immobilized on a solid-phase support. The surface-bound
antibodies selectively capture target molecules from the sample, which could then be detected by a second
round of immunobinding and enzyme amplification. Although detection sensitivity is high, it is
challenging to implement heterogeneous immunoassay in point-of-care diagnostic platforms due to the
multiple washing steps, slow reaction kinetics, and the loss of antibody activity upon immobilization.
Homogeneous immunoassays, on the other hand, are ideally suited for point-of-care diagnostic
platforms as they do not require any manual washing step and features very fast solution phase kinetics.
The only requirement is a way to detect the antibody-antigen complex from free antibodies. This has been
achieved by separating immunocomplexes from the unbound antibodies by gel electrophoresis and
recently by using the ANA structure 2 . In these separation methods, there is always a tradeoff between
signal and separation resolution as molecular dispersion inevitably reduces detection sensitivity. Here,
using the HNA platform, we demonstrate that differential concentration of immunocomplexes allows us
to quantitatively detect low abundance biomarkers. As this device concentrates immunocomplexes instead
of letting them disperse as in normal separation methods, high signals are obtained which facilitates
detection.
In the current study, we examined the human C-reactive protein (CRP) as a model biomarker.
CRP is a pentameric serum protein with a molecular weight of ~115 kDa47-49. During acute inflammation
such as cardiovascular diseases, CRP level in serum is upregulated, and the clinical cutoff value is 3-5
gg/mL. For our experiment, we used the d, = 80 nm HNA device. CRP and 10 gg/mL FITC-labeled
antibody were mixed in 1 x TBE containing 0.5% BSA off chip. After 30 minutes incubation for binding
reaction to occur, the mixture was injected into the HNA device via applied voltage. Migration of the free
antibodies and antibody-antigen complex followed the direction of electroosmosis. In the negative
68
control, there was a uniform fluorescence intensity profile throughout the HNA device, indicating that the
free antibodies do not concentrate in the 80 nm device. With increasing concentration of CRP, a
concentrated fluorescent band starts to appear in the center of the HNA device, indicating formation of
large antigen-antibody complexes which undergo Ogston sieving (Figure 3.8a). In order to study the
effects of electric field strength on the performance of this device, we performed the experiments at 4
different applied voltages (10 V, 20 V, 50 V and 100 V). The fluorescence intensity profiles across the
HNA for different antigen concentrations and different applied voltages are plotted in Figure 3.8b.
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Figure 3.8: A concentration-enhanced homogeneous immunoassay using the HNA device. Quantitative
measurement of biomarkers in a sample can be obtained by differential concentration of the antibody-
antigen complex. a) Experimental results showing behavior of antibody-antigen complex in HNA device
at different antigen concentrations when 20 V is applied across the device. b) Fluorescent intensity
profile of the focused molecules at different target protein concentrations and applied voltage.
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Figure 3.9 shows the dose response curve for detection of CRP molecules using the HNA device. As
before, the fluorescence intensity of the concentrated band increases with the amount of CRP. At very
high dose of CRP, however, the Hook effect was observed due to saturation of the antibody binding sites
that prevent large complex formation.
The field strength (flow speed) affects different sized molecules differently in the HNA device.
We can investigate this effect by looking at the dose response curve for experiments run at different
applied voltages. The concentration factors in the center of the HNA depend on the amount of the
biomolecular complexes ccomplex that are accumulated within their trapping lifetime Ttrap. In Figure 3.9 we
see an interesting effect where the maximum concentration factor was around 1 ptg/mL CRP for low
voltages operation (10 V), but the maxima became 10 gg/mL CRP for high voltage operation (50 V and
100 V). We hypothesize that this crossover is due to the combined effects of trapping lifetime and
accumulation rate of the complexes. At low voltage operation, the trapping lifetime is the dominant effect,
thus the maximum concentration factor was achieved around 1 4g/mL CRP when the largest
biomolecular complexes are formed. At higher voltage operation, the Ogston sieving effect becomes less
dominant50 . As the size dependence of trapping time is reduced, the accumulation rate of biomolecule
complex becomes the dominant effect. There are more, albeit smaller, biomolecule complexes being
formed at 10 gg/mL CRP. Since the accumulation rate depends directly on the concentration of the
biomolecule complex, the maxima in concentration factor shifts to 10 pg/mL CRP at high voltage
operation. The effect of field strength on size-dependent sieving is also apparent from the slope of the
dose response curve. At low CRP concentrations, the slope of the dose response curve is highest at low
voltage operation, indicating better size selectivity at low electric field conditions. Therefore, the
optimum condition for operating the HNA device would be low electric field to best discriminate
different sized biomolecule complexes. From the dose response curves, we can detect CRP concentrations
as low as 10 ng/mL. This value is low enough to conduct clinical diagnosis of CRP (cutoff value 3-5
gg/mL).
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Figure 3.9: Dose response curve for detection of CRP molecules using the HNA device under different
applied voltages.
3.8 Summary
In this chapter, we introduced the HNA device which allows continuous flow size-selective concentration
of biomolecules. This is the first time that a continuous flow size-based concentration method has been
realized, and it would be a useful technique to improve the sensitivities of various biological assays that
utilize size-based fractionation. The concentration capability of this device is particularly useful in
microfabricated lab-on-chip systems, where the low optical path length reduces detection sensitivity. The
continuous flow format also makes this device an attractive sample preparation tool to continuously
purify and concentrate target molecules based on size from a sample before performing downstream
analysis.
In this work, we show how we make use of this device to interrogate biomolecular interactions,
including protein-DNA binding, protein-protein interaction and antibody-antigen binding. The final
example demonstrates a novel method to perform homogeneous immunoassay for biomarker detection at
clinically relevant concentrations. In view of the rapid kinetics and ease of use, size based concentration
could be a new paradigm for rapid quantification of biomarkers in point-of- care diagnostic systems.
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Chapter 4
Multiplexed Single Cell Kinase Activity Assay
Kinases are an important family of proteins that regulate the majority of cell signaling pathways. They
transmit information by catalyzing the phosphorylation of a specific substrate, thus modulating its
activity. As the substrates of kinases are often kinases as well, information can be propagated through
multiple signal transduction pathways, often with signal amplification. Interactions of multiple kinases in
the signal transduction network lead to different outcomes in response to stimuli, which affects cell fate
(Figure 4.1). Because of its importance in cell decision processing, there is tremendous interest in
quantifying the dynamics of kinase activities in cells. Kinases are also receiving widespread attention in
pharmacology industries, as they are important drug targets for diseases such as cancer. To test new
targeted therapeutics, it is critical to develop sensitive analytical tools to detect abnormal activation of
kinase pathways and to monitor their inhibition in response to treatment".
Recent studies have found that many anti-cancer drugs kill most but not all the cells in a tumor,
often resulting in relapse of cancer 3 . It has been proposed that non-genetic cell-to-cell variability in
protein activity, among other things, lead to this different response to drugs4. As most conventional
techniques provide only a population-averaged measurement of the signals within the regulatory pathway,
they do not reflect an accurate picture of a heterogeneous population of cells being in different states of
intracellular processing 5-7. A platform technology that can reliably assay for kinase activity from single
cells is a valuable tool for biologists to study how individual cells develop into different cell fates and
correlate with their phenotype.
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Figure 4.1: Diagram showing part of the cellular signal transduction network. Nodes in the network are
protein kinases that transmit signal downstream by phosphorylating downstream kinases. Note the
interconnectivity between different signaling pathways. Highlighted nodes (AKT, MK2, PKA) are
important kinases that we measure in our assay. (Adapted from review of Hanahan and Weinberg).
4.1 Antibody based method vs direct activity measurement
Currently, phosphospecific antibodies to kinases are widely used to estimate their activity, since many
kinases are themselves activated by phosphorylation. However, the availability of specific and high
affinity antibodies against different kinase isoforms presents a major bottleneck for the general use of this
technique. Furthermore, antibody-based methods could not detect modulation of intracellular kinase
activities due to other post-translational modifications, protein-protein associations such as protein
scaffolds" 1, and drug interaction.
On the other hand, direct kinase activity assays measure the ability of kinases to catalyze
phosphorylation of a target protein or peptide substrate. These assays include measuring the incorporation
of radiolabeled phosphate from [y- P]ATP into a peptide or protein substrate13' 14, mobility shift assays in
which phosphorylated and unphosphorylated substrates are electrophoreticaly separated and quantified 15
16 and a variety of fluorescence based methods including homogeneous time-resolved fluorescence1',
fluorescence resonance energy transfer 8 chelation-enhanced fluorescence 9, and fluorescence
polarizationi8, 20 techniques. A common limitation of direct kinase activity assay is the specificity of the
enzyme towards the peptide substrate. Kinases often have overlapping substrate specificity leading to off-
target cross-reactivity. Therefore, steps need to be taken to first isolate the target kinase from cell lysate
by immunopurification. Otherwise, pharmacological inhibitors of off-target kinases are required to
improve the specificity of the direct kinase activity assays.
4.2 Single cell kinase activity assay
In order to address the issues related to cellular heterogeneity in signal transduction, one would need
measurement of various kinase activities at the single cell level. Currently, the most advanced methods
for single cell level kinase measurement involve imaging live cells that are genetically encoded for a
substrate molecule that can report the activity changes within the cytoplasm" 3 . These live-cell imaging
methods are very powerful as they could yield spatio-temporal information about kinase activation;
however they are limited in the number and types of enzymes that can be measured simultaneously in
single cells. In addition, expressing a reporter molecules involve laborious genetic engineering of a cell
line to encode a fluorescent protein, and could alter the normal function of the cell line. Therefore, while
useful for scientific studies of cell decision processes using cell cultures, it is generally not suitable for
measuring kinase activity in primary cells such as patient-derived tumor samples. A second strategy that
has been developed involves microinjecting fluorescent kinase substrates into single cells, lysing them
and performing capillary electrophoresis to separate and quantify the phosphorylated and
unphosphorylated substrateis, 34-36. In this second method, it is possible to perform simultaneous
measurements of several enzymes within the same cell, although it does not yield any spatial information
about enzyme activation. However, in combination with techniques such as GFP-kinase translocation,
enzyme activation and spatial location can be measured in the same cell' . In all the methods described
above, substrate specificity would be an issue since there is significant substrate cross-reactivity among
intracellular kinases. Since the living cell is a reaction vessel where the kinase catalyzed reaction takes
place, strategies to improve substrate specificity such as addition of off-target kinase inhibitors cannot be
implemented without perturbing the normal function of the cell. In addition, intracellular kinase substrate
reporters are subjected to other cellular processes such as proteolysis and dephosphorylation during
intracellular kinase reaction 5 , thus obfuscating the actual activity of the target kinase.
Ideally, to obtain single cell kinase activity measurement that can be comparable to conventional
bulk lysate kinase activity measurement, it is preferable to rapidly lyse a single cell and allow the lysate to
react with the substrate for a defined period of time, instead of loading substrate into the cell before lysing
it. Substrate loading by microinjection could result in membrane or organelle damage, which in turn
activates other undesirable stress response pathways in the cell 15 . Also, as mentioned above, injected
substrates are subjected to intracellular off-target kinase reaction, proteolysis and dephosphorylation due
to lack of kinase, protease and phosphatase inhibitors. On the other hand, lysing a cell first and then
allowing the lysate to react with substrate preserves the snapshot of cell signaling state during rapid lysis,
and various inhibitors can be added to the reaction mix to increase kinase specificity as well as prevent
proteolysis and dephosphorylation. However, as the intracellular content of a single cell is released during
79
lysis, they immediately undergo a dilution factor proportional to the size of the reaction vessel. This
necessitates an ultrasensitive assay in order to detect kinase activity at such low enzyme concentration.
4.3 Electrokinetic concentration enhanced kinase activity assay
Since the electrophoretic mobility of a kinase peptide substrate is modified upon phosphorylation, we
could use the same concentration-enhanced mobility shift assay platform, described previously in Chapter
2, to increase the sensitivity of kinase activity assay. Furthermore, due to the separation capability of the
concentration-enhanced mobility shift assay platform, it would be possible to simultaneously separate and
concentrate two or more kinase substrates from their phosphorylated product at the same time. This would
allow us to simultaneously monitor several kinase activities from the same sample, and enable users to
measure the interactions between different nodes in the complex signal transduction network.
Figure 4.2 reiterates the key operation of the poly(dimethylsiloxane) (PDMS) microfluidic
electrokinetic concentration chip. Under the voltage configuration shown in Figure 4.2a, ion depletion
zones are created in the sample channels at the vicinity of the ion selective membrane due to
concentration polarization phenomena. The conductivity gradient at the boundary of the ion depletion
zone gives rise to a stable electric field gradient that can effectively focus negatively charged
biomolecules at separate locations where electrophoretic velocity balances bulk flow velocity. In this
work, fluorescently labeled peptides which contained the recognition sequences for specific kinases are
used as substrates. Target kinases in the sample catalyze the phosphorylation of these peptides, leading to
an increase in electrophoretic mobility (Figure 4.2b). Phosphorylated peptides, which have higher
electrophoretic mobilities due to the negative-charged phosphoryl group, are concentrated at the low
electric field region. On the other hand, unphosphorylated peptides have a lower mobility; therefore they
concentrate nearer to the cation selective membrane where the electric field is higher (Figure 4.2c). In
this manner, we can obtain good separation between phosphorylated and unphosphorylated substrates,
while at the same time achieve continuous signal enhancement for greater sensitivity.
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Figure 4.2: a) Ion selective membrane creates a local ion depletion zone with high electric field upon
applying a voltage, b) Active kinases in the sample phosphorylates the specific fluorescent peptide
substrates by adding a phosphoryl group on the serine/threonine residue, c) Unphosphorylated and
phosphorylated peptide substrate concentrate at different locations on the electric field profile due to their
different electrophoretic mobilities.
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4.4 Experimental section
4.4.1 Reagents and chemicals
Unless stated otherwise, all chemicals used in the experiments were purchased from Sigma (St. Louis,
MO). 5-FAM labeled peptide substrates for AKT (GRPRTSSFAEG, Crosstide 37 ) and PKA (LRRASLG,
Kemptide38) were obtained from Anaspec (Fremont, CA). 5-FAM labeled peptide substrate for MK2
(AHLQRQLSIA, MK2tide39) was custom synthesized by Selleck Chemicals (Houston, TX). All other
custom peptides were synthesized by Selleck Chemicals. Recombinant AKT, MK2 (MAPKAPK2) and
PKA kinases were obtained from Invitrogen (Carlsbad, CA). The kinase inhibitors PKI-tide, GF109203X,
PKC inhibitor peptide and Calmidazolium were obtained from Calbiochem (San Diego, CA). Protease
inhibitors (protease inhibitor cocktail III) and phosphatase inhibitors (phosphatase inhibitor cocktail 1)
were also obtained from Calbiochem. Ampholytes (Fluka) were purchased from Sigma (St. Louis, MO).
Table 1 lists the buffer recipes used in the experiments.
Table 4.1: Buffer recipes
Buffer Recipe
25 mM Tris-HC (pH 7.5), 10 mM MgC12, 1 mM ATP, 1 mM DTT,
Buffer A
0.01% Triton X-100, 200 pg/mL BSA
Buffer B 5 mM Tris-HCl (pH 7), 100 pg/mL BSA
50 mM Tris-HC (pH 7.5), 150 mM NaCl, 15 mM MgC12, 5 mM p-glycerolphosphate,
Buffer C
1 mM EGTA, 0.2 mM Na3VO 4,, 0.2 mM DTT, 200 pg/mL BSA
1% Triton X-100, 50 mM p-glycerolphosphate, 10 mM sodium pyrophosphate,
Buffer D 30 mM NaF, 1 mM benzamidine, 2 mM EGTA, 100 pM Na3VO4,, 1 mM DTT,
10 pL/mL protease inhibitors, 10 ptL/mL phosphatase inhibitors
4.4.2 Microchip operation
The microchips were fabricated as described in Chapter 2. Before the experiment, the PDMS device
channels were passivated with 1% BSA for 1 hour to reduce nonspecific binding of the sample to channel
walls. After that, the channels were flushed with DI water 3 times and filled with buffer solution (5 mM
Tris-HCI, pH 7) until the samples were ready to be loaded.
Samples were loaded into each of the five inlet reservoirs and drawn into the microchannel by
applying a brief suction at the outlet reservoir. The liquid height difference between the inlet reservoir and
the empty outlet reservoir caused a well-controlled gravitational flow of sample solution from inlet to
outlet, without any need for external pump.
Electrodes were inserted into the inlet and buffer reservoirs on the chip and connected to a power
supply (Stanford Research Systems, Sunnyvale, CA). To initiate the concentration-enhanced mobility
shift assay, we applied 50 V at the inlet reservoirs while grounding the side channels. An ionic
concentration gradient was induced near the ion-selective membrane by concentration polarization effect.
Meanwhile, charged sample molecules are continuously separated and stacked at the location where its
electrophoretic velocity equals the bulk flow velocity. The fluorescent intensity of the stacked molecules
increases linearly with time while background noise remained constant, resulting in a high signal-to-noise
ratio.
4.4.3 Measurement instrument and image analysis
An inverted epifluorescence microscope IX 71 (Olympus, Center Valley, PA) equipped with a cooled
CCD camera (SensiCam, Cooke Corp., Romulus, MI) was used for fluorescence imaging. A mechanical
shutter which only opens for 100 ms every 5 s when images are taken was used to prevent photobleaching
of the fluorescent molecules. The images were analyzed using the NIH ImageJ software. Flat-field
correction was performed by dividing a reference image of the device taken before each experiment.
Concentrations of phosphorylated and unphosphorylated peptide substrates were assumed to be directly
proportional to the focused peak height as demonstrated in previous work40 4 1 . Phosphorylation ratio was
calculated by dividing the peak height of the phosphorylated substrate by the sum of the peak heights of
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the phosphorylated and unphosphorylated substrates. Dose response curves and statistical analysis was
obtained using Origin 7 software (OriginLab Corp., Northampton, MA).
4.4.4 Recombinant kinase experiment
We first performed an experiment with recombinant AKT and its fluorescent peptide substrate Crosstide
(5-FAM-GRPRTSSFAEG). We first diluted 0.5 sL of the recombinant kinase with 4.5 gL of the
premixed assay buffer (Buffer A supplemented with 1 pM substrate) and incubated at room temperature
for 60 minutes. After that, 1 pL of this mixture is diluted in 99 ptL of run buffer (Buffer B) and 30 pL of
this final sample is used for the concentration-enhanced mobility shift assay. Figure 4.3a shows the
representative results for this experiment. During 15 minutes of electrokinetic concentration, two dictinct
bands corresponding to the phosphorylated substrate (left) and and unphosphorylated substrate (right)
were formed in each sample channel. The fluorescence intensities of these bands increased linearly with
time and both bands were baseline resolved. Since this is a ratiometric assay, we can extract the fraction
of phosphorylated substrate for each sample by dividing the fluorescence intensity of the phosphorylated
substrate band by the total fluorescence intensity of both bands. Kinase reaction velocities can be directly
calculated from these measurements without any need for calibrations. Besides, a ratiometric assay is
relatively insensitive to external influences such as variable flow rate, light intensity etc., and thus is
highly reproducible. Figure 4.3b showed a dose response curve for the recombinant AKT assay. The
limit of detection for recombinant AKT was calculated to be 1 ng/mL.
To demonstrate the general applicability of this assay for activity measurement of other kinases,
we performed a separate experiment with recombinant MK2 and PKA with their respective fluorescent
peptide substrates MK2tide and Kemptide (MK2: 5-FAM-AHLQRQLSIA, PKA: 5-FAM-LRRASLG).
Except for replacing the substrates, the recombinant MK2 and PKA assay was done with the same
conditions as the recombinant AKT experiment. From the dose response curve in Figures 4.4a and 4.4b,
the LOD for recombinant MK2 and PKA were 1.2 ng/mL and 0.7 ng/mL respectively within 15 minutes
of electrokinetic concentration.
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Figure 4.3: Multiplexed electrokinetic concentration-enhanced mobility shift assay for detection of
recombinant AKT activity (a) With increasing recombinant AKT concentration, the phosphorylated
substrate peak increases and the unphosphorylated substrate peak decreases, (b) Dose response curve for
recombinant AKT activity assay. Plotted values indicate the mean ± s.e.m. for duplicate measurements.
The limit of detection was calculated to be 1 ng/mL.
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Figure 4.4: Dose response curves for a) Recombinant MK2 and b) Recombinant PKA activity assay.
Error bars represent standard error from two replicates. Plotted values indicate the mean ± s.e.m. for
duplicate measurements. The limit of detections for recombinant MK2 and recombinant PKA were
calculated to be 1.2 ng/mL and 0.7 ng/mL respectively.
4.4.5 Substrate cross-reactivity
In the experiments with recombinant kinases, the kinase activities can be unambiguously inferred by
measuring the substrate phosphorylation fraction after a fixed amount of time. The concentration-
enhanced mobility shift assay in this current format can be a useful platform in drug development
applications, such as measuring the changes in recombinant kinase activities in the presence of novel
small molecule drugs.
In order to assess the substrate specificity of our kinase of interest, we measured the pair-wise
cross-reactivity between each substrate and kinase. Briefly, 1 pM of each substrate was separately reacted
with a fixed amount (100 ng/mL) of each recombinant kinase in the assay buffer (Buffer A) for 1 hour at
room temperature, and the phosphorylation fraction was measured on the concentration-enhanced
mobility shift assay platform as described previously.
Figure 4.5 shows the results of this experiment. As expected, the degree of substrate
phosphorylation is greatest when a kinase react with its target substrate (Kemptide for PKA, Crosstide for
AKT, MK2tide for MK2). However, this assay also detected a small amount (<10%) of off-target
phosphorylation. This is not surprising as kinases often have overlapping substrate specificity that could
lead to off-target cross-reactivity.
Off-target kinase reactivity could present an accuracy problem when measuring specific kinase
activities in complex samples such as crude cell lysates. Furthermore, the presence of other intracellular
enzymes such as proteases and phosphatase could affect the stability and phosphorylation state of the
substrates. This is one major limitation of many existing single cell kinase activity assays, where
substrates that are microinjected into or expressed within the cell are subjected to the activity of other
intracellular enzymes such as off-target kinases, proteases and phosphatases.
In order to improve the specificity of the kinase activity assays, inhibitors of off-target kinases,
proteases and phosphatases can be added in the reaction buffer. It has been shown that these inhibitors can
effectively suppress the activity of their target enzymes without affecting the activity of the kinase of
interest'. In our subsequent experiments using bulk cell lysate and single cells, we adopted this strategy
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of adding a cocktail of protease, phosphatase and off-target kinase inhibitors to improve our assay
specificity.
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Figure 4.5: a) Experimental results, and b) Analysis showing the pair-wise cross-reactivity between three
kinases (PKA, AKT, MK2) and their substrates (Kemptide, Crosstide, MK2tide).
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4.4.6 Cell lysate experiment
To show the application of this assay with real samples, we repeated the kinase activity experiments with
diluted HepG2 cell lysate. Cell culture, treatment, and lysis were conducted basically as in Shults et a119.
HepG2 cells (a human hepatoblastoma cell line) were obtained from ATCC (Manassas, VA). HepG2 cells
were seeded on 10-cm tissue culture-treated polystyrene plates at Ix105 cells/cm2 in Eagle's minimum
essential medium (EMEM; ATCC) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan,
UT), 100 U/ml penicillin (Sigma, St. Louis, MO), and 100 pg/ml streptomycin (Sigma) and were
incubated at 370 C in 5% C02. One day after seeding, medium was changed to fresh EMEM without FBS.
One day after medium change, HepG2 cells reached confluence and were stimulated with 500 ng/mL
insulin (Sigma) in EMEM (to activate AKT) or 25 pM forskolin (Sigma) in EMEM without FBS (to
activate PKA), or left untreated (EMEM without FBS). For both conditions (activated and unactivated),
cells were placed on ice 30 minutes following stimulation and culture medium was removed. Cells were
lysed with lysis buffer (Buffer D, containing protease and phosphatase inhibitors) for 20 minutes at 4'C
followed by scrapping. Lysates were clarified by centrifugation at 16,000g for 15 minutes at 4'C.
Clarified lysates were analyzed using a bicinchonicic assay (Pierce, Rockford, IL) to determine the total
cellular protein concentration. Stock lysates were divided into single-use aliquot and stored at -80'C.
We first demonstrate the results with AKT kinase activity assay. Insulin stimulation is known to
increase the activity of AKT in vivo. Therefore, we compared the activity of serum starved HepG2 cell
lysate and insulin stimulated HepG2 cell lysate. To perform the cell lysate kinase activity experiment,
assay buffer (Buffer C with 4 jiM PKC inhibitor, 4 pM calmidazolium, 1 pM fluorescent Crosstide, 1
mM DTT, 1 mM ATP, 0.4 pM PKI-tide, 5 RM GF109203X) was prepared in bulk and 18 pL volumes
were aliquoted into separate microcentrifuge tubes. To begin each reaction, 10% (vol/vol) lysis buffer
(Buffer D) or lysate (diluted in lysis buffer to stated concentrations) was added and the contents were
mixed gently. Reaction was carried out at 37 'C for 60 minutes. After that, reaction was stopped by
diluting 1 pL of this mixture in 99 piL of run buffer (Buffer B). 30 jiL of this final sample was used for
the concentration-enhanced mobility shift assay. Figure 4.6a shows the results for this experiment. We
observed no phosphorylated substrate band for the negative control samples (containing lysis buffer but
not HepG2 cell lysate). For the same final cell lysate concentration (down to the lowest tested
concentration of 2.16 pg/mL), the insulin stimulated sample consistently showed a higher fraction of
phosphorylated substrate compared to the serum starved sample, confirming the utility of our assay to
measure changes in cellular kinase activities in response to stimuli. The cells used in this experiment have
about 1 ng of protein per cell. Detection from a final volume of 30 pL run buffer, after a total of 100-fold
dilution of a 2.16 pg/mL of cell lysate, represents kinase assay from ~0.6 cell. This demonstrates the
sensitivity of our assay for single cell level studies of cell signaling pathways.
We also performed similar experiments measuring PKA activity from HepG2 cell lysate.
Forskolin stimulation is known to increase the intracellular level of cAMP and upregulate PKA activity.
The experimental procedure was similar to the cell lysate AKT activity measurement, except that the
substrate was replaced by 1 pM fluorescent Kemptide and PKI-tide (which is a kinase inhibitor for PKA)
was left out. Figure 4.6b shows that consistent with expectation, the forskolin stimulated sample
consistently showed a higher fraction of phosphorylated PKA substrate compared to the serum starved
sample. This shows that our platform can be generally applied to measure activities of different kinases
with high sensitivity from physiological samples.
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Figure 4.6: a) Representative experimental results showing multiplexed electrokinetic concentration-
enhanced mobility shift assay for detection of AKT activity in serum-starved (SS) and 5 minutes 500
ng/mL insulin-stimulated (IS) HepG2 cell lysate, b) Dose response curve of AKT activity in different
concentrations of serum starved and insulin treated HepG2 cell lysate showing upregulation of AKT
activity by insulin, (c) Dose response curve of PKA activity in different concentrations of serum starved
and forskolin (25 pM, 30 mins) treated HepG2 cell lysate showing upregulation of PKA activity by
forskolin. Plotted values indicate the mean ± s.e.m. for duplicate measurements.
4.5 Multi-substrate separation
So far, in both the concentration-enhanced aptarner and kinase activity assays, we have demonstrated
simulataneous concentration and separation of two species (free aptamer vs aptamer-protein complex,
phosphorylated vs unphosphorylated peptide substrate). This phenomenon can be understood by
considering the diagram in Figure 4.7a, which show electrofocusing of two species with different
electrophoretic mobility at the electric field gradient formed around the ion depletion zone boundary. An
examination of Figure 4.7a, which shows electrofocusing of free aptamer and aptamer-IgE complex in 5
mM Tris-HCl buffer without any additives, suggests that the spatial extent where the electric-field
gradient is significant (distance between the two bands) spans only a short distance of the order of 100
42ptm. This is consistent with previous in-situ electric field measurements , which shows a 30-fold
amplified electric field in the ion depletion zone (width ~ 200 pm) compared to outside the depletion
region. This sharp electric field gradient is key to the very high preconcentration factors43 reported for this
device as biomolecules experience a very high trapping force in this steep potential well. Given this
situation, it would be difficult to observe clear separation of more than two analytes, since the region in
which separation could occur is very short and molecular diffusion would cause closely-separated bands
to merge and appear indistinguishable.
In studies related to the signal transduction network, investigators are often interested in
understanding the functional relationship between activities of different kinases in the network. By
measuring and comparing kinase activities between different signaling pathways, we could deduce how
the different input stimuli are integrated and processed to produce different cellular response.
Unfortunately, most current single cell kinase activity assays lack the capability of looking at more than
one single kinase activity at a time.
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Figure 4.7: a) Experimental results and schematic showing simple electrofocusing of free aptamers and
aptamer-IgE complex in 5 mM Tris-HCl buffer without any additives, b) Experimental results and
schematic showing depletion zone isotachophoresis of free aptamers and aptamer-IgE complex in 5 mM
Tris-HCl buffer with 100 pg/mL BSA. Preconcentration of the intermediate mobility species creates an
electric-field plateau which increases the separation distance between the two analytes of interest.
We discovered that addition of an appropriate high-abundant species in the buffer during the
concentration-enhanced mobility shift assay result in a larger separation distance between the two
fluorescent bands. The separation distance increases proportionally to the amount of the high-abundant
species added. Interestingly, the peak width of the focused band remained narrow, suggesting that the
electric field gradient is still very steep despite the larger separation distance. This phenomenon is shown
in Figure 4.7b, where we observed a significant increase in separation distance between the free aptamer
band and the aptamer-IgE complex band in buffer containing 100 pg/mL BSA, all other conditions being
the same.
This phenomenon is thought to be due to preconcentration of an intermediate mobility species
(BSA in this case) to such high concentrations that it is capable of changing the electric field profile
according to the Kohlraush Regulating Function (KRF), as is commonly observed in isotachophoresis
(ITP) experiments. Other experiments and theoretical analysis strongly supports this hypothesis44.
Qualitatively, as preconcentration increases the local concentration of the intermediate mobility species (a
co-ion), the high mobility co-ions in the same regions are displaced in order to maintain electroneutrality.
This leads to a lower conductivity and sustains higher electric field in this region. Continuous
preconcentration of the intermediate mobility species eventually expands the spatial extent of this low
conductivity region, leading to a high electric field plateau.
Figure 4.7b shows the schematic of the electric field profile modulated by preconcentration of a
high abundant intermediate mobility species. The electric field gradient remained steep where focusing of
the free-aptamer and aptamer-protein complex occurs. Meanwhile, the region where the intermediate
mobility BSA focuses forms an electric-field plateau which increases the separation distance. This
staircase-like electric field profile is unique in the aspect that it could increase the spatial separation
resolution between target analytes while still keeping the individual bands narrowly focused at local
regions where the electric field gradient is steep. This suggests a method where we can simultaneously
separate and focus multiple kinase substrates and products by "adding more steps on the staircase" -
adding more intermediate mobility species between the analytes of interest as shown in Figure 4.8. By
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adding suitable spacer molecules with appropriate mobilities at various concentrations, we can engineer
an optimal electric field profile to perform a concentration-enhanced multiple kinase substrate mobility
shift assay.
Substrate 1 E-field
Phosphosubstrate 1
Substrate 2
Phosphosubstrate 2
Intermediate
mobility spacer
Figure 4.8: Schematic showing a strategy to simultaneously separate and focus multiple kinase
substrates. Upon adding suitable spacer molecules with intermediate mobilities at various concentrations,
depletion zone isotachophoresis results in a staircase-like electric field profile that increases the
separation resolution between multiple kinase substrates.
The problem now reduces to how we would design a mixture of spacer molecules for optimal
concentration and focusing. There are two main design considerations: 1) the spacer molecules should
have electrophoretic mobilities in between the two analytes to be separated, 2) the concentration of the
spacer molecules should be sufficient to provide the desired resolution, but not too high to avoid
excessive voltage drop and therefore reduction of electric fields at the analyte focusing areas. In the
absence of any knowledge about the actual analyte and spacer mobilities, one could turn to commercially
available mixtures of compound which contains a wide range of molecules with different mobilities.
Some compounds in this mixture are likely to have the appropriate mobility to act as a spacer for this
purpose. One such mixture is commercially available ampholytes, which are a blend of zwitterionic
compounds commonly used for isoelectric focusing (IEF). Ampholytes are designed to have a continuous
range of isoelectric points and as such the compounds are expected to have a variety of different charges
and mass (and thus different mobilities) at a particular pH. These compounds have also recently gained
renewed interest for use in isotachophoresis as spacer molecules 45' 46. Figure 4.9 illustrates the utility of
ampholytes as spacer molecules in the concentration-enhanced mobility shift assay. According to the
principle of depletion-zone isotachophoresis, compounds in the ampholyte stack in the order of their
mobilities. This creates an extended separation zone where the equilibrium focusing position of individual
fluorescent analytes are well resolved.
Ampholyte stack according to mobilities, form spacer
Figure 4.9: According to the principle of depletion-zone isotachophoresis, compounds in the ampholyte
stack in the order of their mobilities. This creates an extended separation zone where the equilibrium
focusing position of individual fluorescent analytes are well resolved.
We performed experiments in an attempt to two separate fluorescent peptide substrates (5-FAM-
GRPRTSSFAEG for AKT and 5-FAM-LRRASLG for PKA kinases) and their products by adding
different ampholytes (0.001%) to the buffer (5 mM Tris-HCl, pH7). As shown in Figure 4.10, three clear
bands were observed in the channels containing ampholytes with isoelectric points (pI) values ranging
from 5-7 and 3-10. This seem to suggest that ampholyte compounds with pI 8-10 have too low mobilities
while compounds with pI 3-5 have too high mobilities to be appropriate spacers. Despite the complexities
of the ampholyte compounds, it is seen that it could only provide good separation between the
unphosphorylated substrates, since the phosphorylated substrates were still not clearly resolved. This
means that there are no compounds in the ampholytes that are suitable spacers for separating the
phosphorylated substrates.
Phosphorylated A, B, C Kinase substrates A, B, C
pi 8-10
Figure 4.10: Experimental results showing separation of two kinase substrates (Crosstide for AKT,
Kemptide for PKA) and their products by adding ampholytes with different pI ranges to the buffer.
Ampholyte (0.001%, p1 5-7) was effective at separating the unphosphorylated kinase substrates but was
not able to resolve the phosphorylated products from each other.
A similar situation was encountered when we attempted to separate the peptide substrates for
MK2 (5-FAM-AHLQRQLSIA) and PKA from their products by adding ampholytes with pI ranging from
5-7 to the buffer. Figure 4.11 (top two channels) shows that the unphosphorylated MK2 and PKA
substrates were well resolved from each other and from the phosphorylated peptides, but the
phosphorylated MK2 and PKA substrates were not well resolved from each other. We tried a number of
other compounds and found that 2-(N-morpholino)ethanesulfonic acid (MES), one of the Good's buffer,
was an effective spacer for phosphorylated MK2 and PKA substrate and could provide clear separation
between each of the MK2 and PKA substrates and their phosphorylated products (4 bands) when used in
conjunction with ampholytes (0.001%, pI 5-7) in 5 mM Tris-HCl buffer (pH 7) (Figure 4.11).
PKA, pPKA, MK2, pMK2
PKA, pPKA, MK2
PKA, pPKA, MK2, pMK2
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Figure 4.11: Experimental results showing separation of two kinase substrates (MK2tide for MK2,
Kemptide for PKA) and their products by adding ampholytes with different pI ranges to the buffer.
Ampholyte (0.001%, pI 5-7) in conjunction with 10 pM MES was effective at separating the
phosphorylated and unphosphorylated kinase substrates.
There are some inadequacies of using ampholytes as a spacer. As we have just observed, in some
instances the ampholyte compounds could not provide spacer function for our analyte of interest, and we
have to source for other form of spacer molecules. The exact mixture of ampholyte is proprietary, so we
do not know a priori if a compound of a desired mobility is present. Finally, ampholytes are premixed
and optimized to ensure that they cover a uniform range of pI value. When used as spacers in the
concentration-enhanced mobility shift assays, we lose the freedom to arbitrarily tune the electric field
profile by varying the concentration of each individual compound.
Since we are interested in separating peptide substrates and their post-translationally modified
products, a natural candidate for spacer molecules is synthetic peptides. Custom synthetic peptides can be
obtained at low cost and high purity, but one of the most attractive features for our application is that their
mobilities can be tailored by adding different charged and different molecular weight amino acids during
peptide synthesis. Thus, spacer molecules of any mobilities can be designed and synthesized. The
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mobilities of the peptide substrates and spacers can be approximated with the Offord Model47' 48 = Q /
M2 /3. To test this approach, we synthesized 12 different peptides with different mass and charge to be
used as spacer molecules in the concentration-enhanced mobility shift assay. We adpoted a simple
approach to design these spacer peptides: to increase mass we added extra neutral glycine (G) molecules
to the carboxylic acid terminal of the peptides, to increase charge we added extra negatively charged
glutamic acid (E) molecule separated by one glycine molecule to the amine end of the peptide. The
predicted mobilities of the synthetic spacer peptides are placed alongside the predicted mobilities of the
kinase peptide substrates in Figure 4.12. Peptides with mobilities in between kinase substrates or
phosphorylated products that we wish to resolve can be chosen as spacers.
Figure 4.13 shows that be rationally choosing the appropriate peptide spacers, we can
simultaneously concentrate and baseline resolve substrates and products corresponding to three kinases
PKA (substrate: 5-FAM-EELGRTGRRNSI), AKT (substrate: 5-FAM-GRPRTSSFAEG-NH 2) and MK2
(substrate: FITC-EEKKLNRTLSVA). This general capability would allow us to simultaneously monitor
several kinase activities from the same sample and study their functional relationship to yield insights on
the inner-workings of cell regulatory pathways.
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Figure 4.12: Predicted mobilities of the fluorophore-tagged peptide substrates and synthetic peptide
spacers according to the Offord Model R = Q / M2/3. To resolve a pair of analytes of interest, a synthetic
peptide with an intermediate mobility can be chosen as a spacer.
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Figure 4.13: Simultaneous concentration and baseline separation of substrates and products
corresponding to three kinases PKA (substrate: 5-FAM-EEGRTGRRNSI), AKT (substrate: 5-FAM-
GRPRTSSFAEG-NH 2) and MK2 (substrate: FITC-EEKKLNRTLSVA) using rationally designed
synthetic peptide spacers.
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4.6 Single adherent cell culture
In this section, we describe methods that we developed to culture and isolate single cells, as well as
techniques to perform cell lysis, incubation of kinase substrate with lysate and finally transfer of reaction
products to a separate chip where we perform the concentration-enhanced kinase activity assay. Most
cells derived from solid tissues are adherent, and therefore we sought to develop techniques to assay for
kinase activity in adherent cells. While cell handling and various operations such as lysis have been
demonstrated on suspension cells49-52, they are considerably more challenging for adherent cells. Also,
since we are developing tools that would ultimately be used by biologists in their investigations, we aim
to develop our assays to be compatible with current methods of cell culture, keeping to standard materials
such as polystyrene, glass, silicone and avoiding complicated fluidic handling systems such as growing
cells in enclosed microfluidic channels.
To comply with standard tissue culture techniques, we decided to grow cells in an open system
where cell culture media and gases can diffuse freely instead of closed microfluidic channels where media
needs to be perfused constantly to supply nutrients and remove waste. Conventional single adherent cell
isolation is performed by serial dilution in multiwell plates. However the large volumes of this well plates
(-100 pL) means that once lysed, the intracellular contents of a single cell is extremely diluted and it
would be far below the detection limit of any assay available. Growing single cells in smaller wells would
reduce the dilution factors to make single cell kinase activity assay possible. One attractive option is the
commercially available CultureWell (Grace Biolabs) setup, where ptL volume cell culture chambers are
defined by non-cytotoxic silicone well gaskets on coverglass. However, as commercially available
CultureWell system consists of only 16 wells, too few for our application, we decided to fabricate our
own silicone gasket based cell culture chamber arrays that best suit our purpose.
To fabricate the silicone gasket wells, we first start with a stack of two thin PDMS sheets (250
pim, Silicone Specialty Products). PDMS is a non-cytotoxic silicone material that has been used
successfully in many cell cultures. To make the hole arrays (7x7, 2.8 mm pitch), we initially manually
punched through the PDMS sheets with a 500 pm OD biopsy punch (Harris). This array was designed to
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fit within the boundaries of a 22 mmx22 mm coverglass slip. Later, we successfully automated the hole-
punching process by mounting the biopsy punch on a CNC drilling machine (Sherline) and using open-
source software (Modrilla) to control the exact coordinates where the holes will be drilled. The automated
hole punching process took less than 3 minutes to punch 49 holes.
To prepare the microwells for cell culture, the silicone sheet with punched holes was treated with
oxygen plasma (Harrick) for one minute and bonded permanently onto a piece of acid washed coverglass
slip (22 mmx22 mm). The oxygen plasma treatment sterilized the PDMS gasket and increased its
wetability to facilitate cell seeding in the later step. The devices were immediately immersed in lx
Phosphate Buffered Saline (PBS) after bonding and placed in a vacuum dessicator for 10 minutes to
remove any trapped bubbles. Devices were kept in 1x PBS until ready to use.
To seed single cells in the microwells, the devices were first immersed in 1mL of complete cell
culture media in a 35 mm tissue culture polystyrene plate. Freshly trypsinized HepG2 single cell
suspension was diluted to 1250 cells / mL in 1 mL complete culture media and added to the tissue culture
plate. The cell suspension was mixed by gently pipetting up and down and allowed to settle overnight at
37 *C in 5% C02. Cells settled randomly into the microwells following a Poisson distribution. At the
above cell seeding density, on average 30% of the 49 wells contained single cells.
4.7 Single cell lysis and kinase reaction
There are several methods reported in the literature on performing single cell lysis53 , these include optical
lysis using a laser pulse15, 34, 35, 54-56, electrical lysis 57, 58, chemical lysis59' 60 and ultrasonic lysis61 . We
choose to implement an ultrasonic lysis method since it does not require expensive and complicated
setting, does not require integrated electrodes, and result in minimal chemical denaturation of the kinase
molecules. Ultrasonication is a proven technique for cell lysis and has been shown to be able to lyse cells
in microfluidic devices in less than 10 S61*. It also has the advantage of being a parallel process where cells
in an array of microwells can be simultaneously lysed. The mechanism of ultrasonic cell lysis is thought
to be due to extreme shear forces and pressure transients generated during microbubble cavitation. The
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ability to lyse cells in a very short period of time makes this an attractive method for use in signal
transduction studies where fast lysis is required to minimize changes in the kinase activities during the
process.
We developed a technique to ultrasonically lyse single cells confined in nL size microwells, so
that the released intracellular kinases can catalyze phosphorylation of peptide substrates that we pre-
added to the wells just before lysis. Since the enzymes and substrates are confined in nL sized chambers
which prevent further dilution, there are at effective concentrations which allows kinase reaction to occur
with reasonable kinetics. There approach is parallel to many recent works that make use of microfluidic
confinement to increase effective concentrations of target biomolecules and enable ultrasensitive
detection62 64 . One unique advantage of this approach compared to many existing single cell kinase
activity assay is that various inhibitors (for off-target kinase, protease, phosphatase) can be added in the
reaction buffer to increase specificity, reduce cross-talk, maintain stability and preserve phosphorylation
states in the kinase assay.
To perform cell lysis in reaction buffer, the cells (treated or control) in microwells were first
washed once with ice-cold PBS and followed by ice-cold Tris-Buffered Saline (TBS). The microwells
were then overflowed with kinase reaction buffer (Buffer C with 2 pM fluorescent substrate, 1 mM ATP,
0.01% Triton X-100, 10 gg/mL protease and phosphatase inhibitors, and inhibitors of off-target kinases)
containing the substrates. Next, the wells were sealed with a piece of Kapton tape and the excess substrate
was squeezed out. The sealed device was then immediately placed in a ultrasonic water bath and
sonicated at full power for 30 s to lyse the cells within the microwells. Cell lysis was confirmed by
imaging under the microscope. The kinase reaction was then allowed to proceed in the sealed microwells
for 90 minutes in a 37 'C incubator.
Next, we developed a method to transfer the reaction mixture from the nL reaction chamber into
the biomolecular concentration device. Since fluid handling in the nL scale is challenging, we adopted the
strategy of diluting the nL reaction mix into a larger volume (pL) to facilitate transfer. This dilution step
also effectively stops the kinase reaction, resulting in an endpoint assay. This strategy of confinement
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followed by dilution has the advantage that kinase reaction can occur with an appreciable rate during the
confinement incubation period, while the later dilution step stops the reaction and facilitate fluid handling.
The preconcentration capability of our device would provide the additional sensitivity needed to detect
signal from this diluted mixture. To perform the dilution step, another piece of PDMS (1 mm thick) with
2 mm diameter holes (2 mm biopsy punch) was aligned and reversibly bonded on top of the Kapton tape
side of the device to form dilution chambers. 5 sL of the dilution buffer (Buffer B) was pipetted into each
dilution chamber. This device is then placed in a dry 35 mm polystyrene dish for imaging under an
inverted microscope. While looking under the microscope, we pierced through the Kapton tape above
using a hypodermic needle (27G1/2, BD). While the reaction product could diffuse into the dilution
buffer, the process could be slow. We enhanced the mixing of the reaction product and the reaction buffer
by floating the device above an ultrasonic bath operating at low power for 30 s. The mixture in each
dilution chamber was pipetted into a 96 well PCR plate and further topped up to 12 pL with dilution
buffer before being stored at -80 'C. Figure 4.14 shows the complete process flow for the cell culture,
lysis, reaction and fluidic transfer operation.
Figure 4.15 demonstrates successful cell lysis using the ultrasonic method. The left panel show
adherent HepG2 cells growing in the microwells. The cells were pre-labeled with a cytoplasmic live-cell
dye (Cell Tracker Orange, Invitrogen) before cell seeding to facilitate cell tracking. Upon sealing with
Kapton tape and 30 s ultrasonication, the cells are lysed, releasing their intracellular contents including
the cytoplasmic dye (right panel). Wells with initial larger number of cells are more fluorescent after
ultrasonication due to release of larger amounts of cell tracker orange dye.
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9. Pierce Kapton tape with hypodermic needle to release
content of small chamber into dilution buffer. Mix. Collect
contents from big chamber to be loaded into device
Figure 4.14: Complete process flow for the cell culture, lysis, reaction and fluidic transfer operations.
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Figure 4.15: Left panel shows HepG2 adherent cells (labeled with Cell Tracker Orange dye) growing in
500 pm diameter microwells. Right panel shows images of microwells after 30s ultrasonic lysis.
Intracellular contents including the cytoplasmic live cell dye were released and confined in the microwells
108
122 cells
33 cells
5 cells
0 cell
4.8 Concentration-enhanced single cell kinase activity assay
To demonstrate the concentration-enhanced single cell kinase activity assay, we performed cell seeding at
low densities to obtain microwells that contain single HepG2 cells. After allowing cells to attach and
spread in a 37 *C incubator overnight, the cells were lysed, incubated with kinase substrate and the
reaction product was collected as described in the previous section. Each time, 5 different samples each
containing 10 pL of the diluted reaction product was loaded into the biomolecular concentrator device to
perform the concentration enhanced mobility shift assay.
Figure 4.16 shows the results of single cell kinase activity assay using AKT as a substrate (4 gM
PKC inhibitor, 4 pM calmidazolium, 0.4 gM PKI-tide and 5 pM GF109203X added to inhibit off-target
kinase activity). The top panel shows the fluorescence image of the cells just before lysis while the
bottom panel shows the corresponding concentration-enhanced AKT activity assay. In the samples
corresponding to wells with no cells (negative controls), we saw only one band corresponding to the
unphosphorylated AKT substrate. On the other hand, in samples corresponding to wells containing one
cell, we saw two fluorescent bands corresponding to the phosphorylated and unphosphorylated AKT
substrate. This result shows conclusively that our assay can detect AKT kinase activities from single cells.
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BFigure 4.16: a) Fluorescence image of single HepG2 cells growing in microwells before lysis, b) the
corresponding concentration-enhanced AKT activity assay. In the samples corresponding to wells with no
cells (negative controls), we see only one band corresponding to the unphosphorylated AKT substrate. On
the other hand, in samples corresponding to wells containing one cell, we see two fluorescent bands
corresponding to the phosphorylated and unphosphorylated AKT substrate.
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One additional capability of our device is that it is straightforward and possible to look at total
kinase activity from multiple cells that growing in the same well. This might be interesting to compare
kinase activities when two cells are growing next to or in contact with each other versus two cells that are
growing far apart in the well. Since our biomolecular concentrator can currently assay for five samples
simultaneously (this is not the upper limit - recently we have demonstrated multiplexing of up to 128
channels 65), we can obtain reasonable assay throughput to perform some statistical analysis. Figure 4.17
shows the results of single, double and triple cells kinase activity assay using MK2tide as a substrate to
measure MK2 activity. As expected, there is a clear trend indicating that total kinase activity increases
with the total number of cells in the well. The variance in the total kinase activity also increases with the
number of cells, as expected for sum of random variables from independent identical distributions. We
observed that there are some outlier points in the activity distribution. Upon reference with the cell image
taken before cell lysis, we found that these high kinase activities were due to abnormally large cells. This
highlights the ability to correlate single cell phenotype with cellular kinase activity in our method.
111
C\|
0.7-
0.6-
0.5-
0.4-
0.3-
0.2-
0.1-
0.0
# cells
Large cell Sma il cell
Figure 4.17: Scatter plot shows the total kinase activities in microwells containing zero, one, two and
three cells. Total kinase activity increases with the number of cells. Outlier data points correspond to large
cells.
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We could observe the relationship between single cell phenotype (e.g. cell size) and single cell
kinase activity by plotting the kinase activity vs phenotype measure on a scatter plot (Figure 4.18). Using
total cellular fluorescence (due to live cell labeling) as a proxy for cell size, we found that the total kinase
activity follows a linear trend with respect to cell size. This is not surprising as kinases are intracellular
enzymes, and the concentration (instead of absolute amount) of active kinase in a cell is the regulated
parameter that determines cell fate. From this scatter plot, we can also decouple the effects of cell size and
obtain the single cell heterogeneity in kinase activity per unit cell volume, which would arguably be a
more relevant factor in single cell signal transduction studies.
113
4-.
0.8
0.7
0.6-
Cell size variation
> 0.5-
0.4- 0 0 cell
U 1 cell
CJ 0.3- M 2 cells
0.2- " 3 cells
S. "- Linear fit
0.1-
0.0-
0 50000 100000 150000 200000 250000
Integrated cell fluorescence
Figure 4.18: Linear relationship between kinase activity and total cell volume (using cell fluorescence as
a proxy).
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In Figure 4.19, we plotted the single cell MK2 activity vs cell number after normalizing by the average
cell volume. We saw that this transformation removed the outlier points. We performed a Student's 2-
tailed t-test and showed that the samples with different number of cells have significantly different
normalized kinase activities. Thus, we demonstrated that our assay have both single cell sensitivity and
single cell resolution.
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Figure 4.19: MK2 activity vs cell number after normalizing by the average cell volume. Different
numbers of cells have significantly different normalized kinase activities by Student's 2-tailed t-test. This
shows the concentration-enhanced kinase activity assay has both single-cell sensitivity and resolution.
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4.9 Concentration-enhanced single cell multiple kinase activity assay
Finally, we performed experiments to assay for multiple kinase activities in single cells. The experimental
protocol was the same with the exception of addition of multiple substrates in the reaction buffer. Spacer
molecules (0.001% Ampholyte pI 5-7, 10 sM MES) were added in the dilution buffer to enable
simultaneous concentration and separation of multiple substrates. In Figure 4.20, we demonstrated that
we can simultaneously measure MK2 and PKA activities in single cells. Multiple kinase activity
measurement from single cells is currently very challenging to perform using existing techniques, yet it
could provide vital clues about the functional relationships between different pathways in the signal
transduction network. We believe that our platform can bridge this technological gap.
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Figure 4.20: Concentration-enhanced multiple kinase activity assay (for MK2 and PKA). a) Images of
cells in microwells before lysis, b) Experimental results showing concentration-enhanced multi- kinase
activity assay, c) Electropherogram showing baseline separation of the two fluorescent substrate and
product pairs.
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4.10 Summary
In this chapter, we outlined the use of concentration-enhanced mobility shift assay platform to measure
cellular kinase activity with high sensitivity. We also developed a new capability to separate multiple
species in the concentration-enhanced mobility shift assay platform by using ampholytes or rational
design of peptide substrate and spacers. This capability enables users to perform multi-kinase profiling
using different substrates.
To enable single cell kinase assay, we have developed technology to first grow, isolate and
observe single adherent cells, followed by parallel cell lysis and enzyme reaction in confined nL
chambers, and lastly methods to recover reaction products and transfer to a separate chip for analysis. By
combining these methods, we demonstrated kinase activity assay with single cell sensitivity and
resolution. We also demonstrated multiple-kinase activity assay with single cell sensitivity.
Although we have only demonstrated this platform with three kinases, it is straightforward to
apply this technique to assay for various other kinases on different cell types. This platform is an enabling
technology which allows for quantitative measurement of multiple cellular kinase activities at single cell
level. We believe that it could be a generic and powerful tool for diagnostics, drug development and
systems biology research.
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Chapter 5
Conclusion
5.1 Thesis contribution
With recent advances in basic science, we understand a lot more about disease pathogenesis than we did
several decades ago. Most of the diseases can now be fully treated or kept under control if diagnosed at an
early stage, leading to a drastic improvement in quality of life. However, the healthcare infrastructures for
disease diagnosis and surveillance have lagged behind medical progress. Most countries in the world have
centralized medical centers and laboratories in cities, but access to adequate healthcare is limited at
remote areas. This problem is most serious in resource poor regions, which includes many developing
countries. Millions of people are dying each year from diseases that are treatable due to lack of early
diagnosis. With increasing global connectivity, some of these endemic diseases can even be global health
threat. In recent years, there has been resurgence of many diseases such as malaria and various flu viruses.
As part of the Global Health Initiative, health workers are tasked to rapidly diagnose diseases and
administer proper treatment at point-of-care in remote and resource-poor settings. To do so, it is critical to
develop portable and sensitive diagnostic technologies.
Despite advances in laboratory based biomolecule detection systems that has enabled
unprecedented sensitivity, these technologies are not readily adapted to point-of-care diagnostics systems
due to many practical limitations. As a result, current point-of-care diagnostics products in the market are
still fundamentally based on technologies developed decades ago. Recent developments in micro total
analysis systems (pTAS) have shown promises to address these problems. Microfluidic platforms have
been developed to integrate multiple functionalities in a single chip, leading to many successful portable
lab-on-chip systems that can perform multistep bioanalysis. Nevertheless, many of these microchip-based
assays are still lacking in sensitivity due to inferior portable detection instruments and the inherent low
optical path lengths of microfluidic devices. As ease of use is an important criterion, many widely used
121
platforms in laboratories such as the heterogeneous assay formats might be unsuitable for these portable
diagnostic devices due to the complicated procedures. Finally, there are reagent compatibility issues such
as the limited stability of antibodies upon storage.
To address these problems, this thesis has focused on using micro/nanofluidic technologies to
alleviate several critical bottlenecks of biosensing in lab-on-chip devices. First, we developed a
microfluidic platform to amplify signal for homogeneous mobility shift assay. Using this platform, we
could boost the sensitivity of an aptamer based mobility shift binding assay for biomarker detection. We
demonstrated that this technique can be used for sensitive detection of multiple biomarkers (IgE and HIV-
1 RT) and in real sample condition (10% serum). This work addresses the sensitivity shortcomings of
using aptamers as alternative capture agents in point-of-care applications. Furthermore, this method has
an advantage over many other assays since it is rapid, uses low voltage and can be multiplexed.
Next, we have developed a herringbone nanofilter array device for continuous flow size-selective
concentration of biomolecules. Among other things, this platform can be used to perform homogeneous
immunoassays for rapid quantification of biomarkers. A cardiac biomarker, CRP, was detected using this
device at clinically relevant concentrations. While the use of nanostructures to separate molecules has
been previously reported, the novel biomolecule concentration capability demonstrated here would
improve the sensitivity of such assays, particularly when low optical path length in typical lab-on-chip
devices reduces detection sensitivity.
Lastly, these homogeneous signal amplification platforms are useful tools for scientific studies.
As an example of application, we are able to measure cellular kinase activities with very high sensitivity
using the electrokinetic concentration-enhanced mobility shift assay. We have also developed technology
to isolate, grow and lyse single cells, and use our platform to measure kinase activities from single cells.
By rational design of peptide substrates and spacers, we developed a new capability to separate multiple
analytes in the concentration-enhanced mobility shift platform. This enables users to obtain simultaneous
measurements of multiple cellular kinase activities that could reveal important information about their
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functional relationships. To the best of our knowledge, this is one of the very few measurement
technologies that enables the direct detection of many kinase activities from a single cell.
5.2 Directions for future research
The field of micro/nanofluidics is relatively young, as many basic principles that govern their operation
are still being worked out. On the other hand, these devices tremendous design flexibility, and new
applications are discovered from time to time. The novel phenomena presented in this thesis could lead to
exciting possibilities of new applications and better scientific understanding of fluid behaviors in the
microscale.
In the course of completing this thesis, we came across several interesting ideas that we have yet
to explore fully in view of the scope of the thesis. We briefly outline some of these ideas below as topics
for future research.
5.2.1 Concentration-enhanced mobility shift assay
The concentration-enhanced mobility shift assay principle is truly a platform technology. It can be readily
adapted for various applications, as we have done so for the aptamer-based biomarker assay in Chapter 2
and multiplexed kinase activity assay in Chapter 4. From an application point of view, it can be easily
modified to improve the sensitivity of various homogeneous binding assays (e.g. immunoassays, protein-
protein interaction, and protein-DNA interaction) and enzymatic assays (e.g. protease activity assay and
other post-translational modification assays) which involve mobility shifts.
Another potential application of this platform is for high sensitivity affinity analysis of binding
assays. Recently, it has been demonstrated that Nonequilibrium Capillary Electrophoresis of Equilibrium
Mixtures (NCEEM) can be used to obtain equilibrium binding constant and complex decay rate constant
of protein-DNA interactions, by measuring the characteristic peaks and exponential decay curves of the
electropherogram'.In the concentration-enhanced mobility shift assay, we believe that additional kinetics
information about biomolecular binding reaction can be obtained by considering the electropherogram
profile and concentration rates of the analytes. Furthermore, due to the continuous injection and
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accumulation of analyte which improves the signal, low affinity binding interaction can be measured.
This could be useful in applications such as characterization of binding affinity between transcription
factors and DNA promoter sites, and screening for aptamers with distinct binding affinity parameters.
In this thesis, we have shown sensitive detection using the mobility shift assay format, where the
relative abundance of analytes with different mobilities is measured by two distinct bands in the
electropherogram. An alternative detection modality using this platform can be suggested based on the
isotachophoretic properties of the electrokinetic concentration process. We have shown that addition of
intermediate mobility spacers would increase the separation distance between the two distinct bands, and
the separation distance is proportional to the amount of spacer added. Based on this observation, we can
envision a scheme where we can detect a nonfluorescent analyte based on the amount of separation that it
induces between two fluorescent markers which have higher and lower mobilities respectively compared
to the analyte of interest. Similar schemes have been previously reported in isotachophoresis systems2 -4,
but the continuous injection scheme in our platform could potentially allow higher detection sensitivity
upon long period of electrokinetic concentration. This detection modality would enable sensitive
measurements of chemical analytes and small biomolecules such as metabolites where no effective
affinity binding agents are available.
5.2.2 Size-based concentration of biomolecules using herringbone nanofilter array
We have demonstrated the use of herringbone nanofilter array for analytical measurements such as
protein-DNA interactions, protein-protein interactions and homogeneous immunoassays. As this is a
platform technology, it can be adapted to improve the detection sensitivity of other size-based
fractionation assays. Due to its fabrication compatibility, it could serve as a useful sample
preconcentration module for microfabricated nanostructure based separation methods.
Another research direction that could be pursued is the use of this size-based concentration
concept for sample preparation. Although the throughput of the current device is too low for this purpose,
there are well established methods to increase throughput such as using high aspect ratio nanochannels'
and self-assembled colloidal particle packing techniques 6-8. The major challenge of biomarker detection in
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complex biofluids is the sheer complexity of the samples. Most of the plasma proteins are introduced by
low-level tissue leakages and are generally present at very low concentrations (<< pg/ml), while others,
such as albumin, are present in very large amounts (>> mg/ml). For biomarker detection in blood serum,
it is well documented that the high-abundance serum proteins (mostly albumin and immunoglobulin)
present significant limitation to the detection specificity and sensitivity. The specificity and sensitivity of
biosensing and detection is critically dependent on the effectiveness of sample pre-fractionation and pre-
separation processes. By continuous size-based fractionation and concentration of sample, we can remove
the high-abundance molecular background and enhance the sensitivity of downstream detection modules.
The nanofilter array based separation component will be able to function without gelatinous materials or
complex and expensive surface chemistry, thus allowing for an easy integration within the common point
of care diagnostic platform and convenient implementation in resource-limited settings.
5.2.3 Multiplexed single cell biological activity assay
Finally, on the scientific front, our platform could be used as an important tool to detect various cellular
biological activities with very high sensitivity. We have demonstrated the ability to measure intracellular
kinase activities from single cells. Other single cells activity assays, such as secretion of protease from
single cell into the media and measurements of metabolites from single cells, could also be potentially
realized in this platform.
With this sensitive tool providing single cell measurements that were previously very difficult to
obtain, we can start to explore some fundamental biological questions. This technique can be combined
with other single-cell analysis techniques such as RT-PCR to correlate between gene expression and
protein activity. We can study how individual cells in different states (cell cycle, morphology etc.)
respond to external stimuli such as cytokines. Imaging based phenotypical assays such as measurement of
the migration capability of individual cells, when coupled with the single cell kinase activity profile
assay, would enable us to better understand the complex cellular decision processing. We believe that
this platform could be a generic and powerful tool for diagnostics, drug development and systems biology
research.
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